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ARTICLE 
 
The Missing Link: U.S. Regulation of 
Consumer Cosmetic Products to Protect 
Human Health and the Environment 
VALERIE J. WATNICK* 
 
 
In August 2012, a well-known baby shampoo company 
announced its intention to remove multiple toxic substances from 
nearly all of its products by 2015.1  The announcement came on 
the heels of its earlier promise to remove these chemicals from 
just its baby products by 2013.2 
While the long timeframe of this planned corporate action—
three years—is shocking, it is even more worrisome that these 
 
* Professor Valerie J. Watnick is Chair and Professor of the Department of 
Law at Baruch College, Zicklin School of Business, City University of New York.  
She teaches environmental law and business law at Baruch, and has published 
multiple articles on toxics regulation, risk assessment, and the regulation of 
pesticides.  An earlier version of this research was presented at the Hawaii 
International Conference on Business Law in May 2013 in Honolulu, Hawaii.  
Prof. Watnick is a graduate of Cornell Law School, class of 1988, and Bucknell 
University, class of 1985. 
 1. CBS News Staff, Johnson & Johnson to Phase Out Potentially Harmful 
Chemicals by 2015, CBSNEWS (Aug. 15, 2012, 2:05 PM), http://www.cbsnews. 
com/8301-504763_162-57493890-10391704/johnson-johnson-to-phase-out-
potentially-harmful-chemicals-by-2015/.  Johnson & Johnson has reportedly 
made good on its promise to remove formaldehyde and 1,4-dioxane from its baby 
shampoo.  Katie Thomas, The ‘No More Tear’ Shampoo, Now with No 
Formaldehyde, N.Y. TIMES (Jan. 17, 2014), http://www.nytimes.com/2014/01/18/ 
business/johnson-johnson-takes-first-step-in-removal-of-questionable-chemicals-
from-products.html?_r=0. 
 2. CBS News Staff, supra note 1; see also Associated Press, Group: 
Johnson’s Baby Shampoo a Cancer Risk, CBSNEWS (Nov. 1, 2011, 2:55 AM), 
http://www.cbsnews.com/8301-204_162-20128253/group-johnsons-baby-
shampoo-a-cancer-risk/. 
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substances, including formaldehyde, a known carcinogen,3 and 
1,4-dioxane, a substance linked to cancer in animal studies and 
classified by the U.S. Environmental Protection Agency (EPA) as 
a probable human carcinogen,4 were even linked to products 
designed for babies in the first instance.  To complicate matters 
further, not all of these toxic substances are even listed on 
product labels.  Formaldehyde, for example, is released over time 
from the interaction of substances in the shampoo with the toxic 
quaternium-15, which, until recently, was present in these 
products and found on product labels.5 
The other shocking part of this corporate announcement is 
that these products are not from some unknown manufacturer 
sold at the fringe of U.S. commerce.  Rather, they come from a 
corporate giant that sells cosmetic products in widespread use 
every day—all over the country.  The news highlights the popular 
consumer misconception that federal cosmetic law is protective of 
human health.6  In reality, federal law simply does not prohibit 
the creation of carcinogens or the addition of other toxins in 
cosmetic products in the United States.7  To put a bleaker face on 
 
 3. The EPA lists formaldehyde as a “probable human carcinogen” that has 
been shown to cause cancer in animals.  Integrated Risk Information System: 
Formaldehyde, EPA, http://www.epa.gov/iris/subst/0419.htm (last visited Feb. 
19, 2014); An Introduction to Indoor Air Quality, EPA, http://www.epa. 
gov/iaq/formaldehyde.html (last visited Feb. 19, 2014).  Formaldehyde is also a 
skin, eye, and respiratory irritant.  CBS News Staff, supra note 1. 
 4. Technology Transfer Network – Air Toxics Website, 1,4-Dioxane (1,4-
Diethyleneoxide), EPA, http://www.epa.gov/ttnatw01/hlthef/dioxane.html (last 
visited Feb. 19, 2014). 
 5. CBS News Staff, supra note 1.  Another worrisome chemical that causes 
the release of formaldehyde in cosmetic products is imidazolidinyl urea.  This 
man-made chemical has been studied by the National Cancer Institute and was 
nominated as early as 2003 for inclusion in the National Toxicology Program.  
TECHNICAL RESOURCES INTERNATIONAL, INC., IMIDAZOLIDINYL UREA 1 (2004), 
available at http://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/ 
imidazolidinylurea_508.pdf.  When paired with parabens, imidazolidinyl urea is 
one of the most widely used cosmetic preservatives in the world.  Id.  Another 
commonly used substance in personal care products is DMDM hydantoin, which 
also causes the release of formaldehyde over time.  Katie Thomas, Johnson & 
Johnson to Remove Formaldehyde from Products, N.Y. TIMES (Aug. 15, 2012), 
http://www.nytimes.com/2012/08/16/business/johnson-johnson-to-remove-
formaldehyde-from-products.html?_r=0. 
 6. An August 2012 CBS News story contains this shocking statement: “[T]he 
U.S. Food and Drug Administration doesn’t regulate cosmetic products.”  CBS 
News Staff, supra note 1. 
 7. See id. 
2http://digitalcommons.pace.edu/pelr/vol31/iss3/1
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U.S. cosmetics regulation, the company in question had already 
removed these hazardous substances from its products for sale in 
other regions, such as the United Kingdom and Scandinavia.8  
Worse still, consumers in the United States willing to pay more 
for their baby shampoo could purchase the company’s “natural” 
baby shampoo, a product marketed and sold without a dose of 1,4-
dioxane.9 
Unfortunately, the headline from this baby shampoo giant is 
only the tip of the iceberg with regard to the regulation of 
consumer cosmetics.  For the average U.S. consumer, there is an 
enormous “gaping hole”10 or “missing link” in federal law that 
allows these questionable product formulations. 
The Safe Cosmetics and Personal Care Products Act of 2013 
(House Bill 1385) would require the U.S. Food and Drug 
Administration (FDA) to finally set rules banning carcinogens 
and many toxins from cosmetics in the United States.11  The 
Cosmetics Safety Enhancement Act of 2012 (Enhancement Act),12 
introduced by Representative Frank Pallone, Jr. (D-NJ), and the 
Cosmetic Safety Amendments Act of 2012 (Amendments Act),13 
introduced by Representative Leonard Lance (R-NJ) were 
likewise attempts to begin to strengthen the regulation of U.S. 
cosmetics. 
 
 8. Toxic Baby Shampoo: Johnson & Johnson Agrees to Global Reformulation 
Under Pressure from Health Groups, THE CAMPAIGN FOR SAFE COSMETICS (Nov. 
1, 2011), http://safecosmetics.org/article.php?id=888. 
 9. CBS News Staff, supra note 1.  The cosmetics industry is a $60 billion per 
year industry, and it has lobbied against stricter regulation.  Jim Avila, FDA 
Regulation of Cosmetics Nears Despite Industry Objections, ABCNEWS (Apr. 30, 
2012, 9:07 PM), http://abcnews.go.com/blogs/lifestyle/2012/04/fdas-regulation-
over-cosmetics-nears-despite-industry-backlash. 
 10. Then-U.S. Representative Edward Markey (now Massachusetts Senator), 
the 2011 sponsor of the Safe Cosmetics Act, said the 2011 version of the Act 
would close a “gaping hole” in federal law.  Associated Press, J&J Steadily 
Removing Toxins from Baby Products, THE CAMPAIGN FOR SAFE COSMETICS (Nov. 
16, 2011), http://safecosmetics.org/article.php?id=907. 
 11. See Safe Cosmetics and Personal Care Products Act of 2013, H.R. 1385, 
113th Cong. (2013), available at http://www.govtrack.us/congress/bills/113/ 
hr1385.  This bill was introduced in March 2013 and has been referred to 
committee.  Id. 
 12. See generally Cosmetics Safety Enhancement Act of 2012, H.R. 4262, 
112th Cong. (2012). 
 13. See generally Cosmetic Safety Amendments Act of 2012, H.R. 4395, 112th 
Cong. (2012). 
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Neither of these latter bills, however, went far enough to 
address the fundamental weaknesses in how we regulate toxic 
substances in consumer products and in U.S. commerce generally, 
and previous versions of the House Bill 1385 stalled in 
committee.  The Act seems unlikely in any forthcoming 
Congressional session to garner necessary support.14 
This article explores these lax regulatory efforts and their 
connection to risk assessment, and proposes changes to our 
current toxics regulatory paradigm.  Part I of this article explores 
our current regulatory approach for consumer cosmetics.  Part II 
discusses the specific and dire concerns regarding chemicals that 
are suspected carcinogens and those suspected of disrupting the 
human endocrine system.  The article argues in Part III that 
because the framework for our current regulation of consumer 
cosmetic products is not designed to be protective of human 
health, our regulatory paradigm must shift dramatically in the 
future if this is to become our true goal.  Part IV of the article 
compares our federal efforts to regulate toxic substances in 
cosmetics with those in other developed countries and at the state 
level in the United States.  This section concludes that we lag far 
behind in our health protective regulatory efforts relative to other 
jurisdictions.  If we are to make the protection of human health a 
fundamental goal of our toxics regulatory system and specifically, 
our cosmetic product regulation, we must change our normative 
goals and operate from a more precautionary stance.  In Part V, 
the article reviews past and current federal legislative proposals 
regarding cosmetic regulation, and makes suggestions on how the 
current proposal could be strengthened to make U.S. cosmetics 
safer, and have a greater potential to protect human health. 
 
 14. See H.R. 1385; see also infra note 365 and accompanying text. 
4http://digitalcommons.pace.edu/pelr/vol31/iss3/1
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I.   REGULATION OF COSMETICS 
A.   History of the United States’ Regulatory System 
a.   The Federal Food and Drugs Act 
Although federal regulation of cosmetic products in the 
United States did not begin until 1938,15 the course of early 
regulatory efforts regarding food, drugs, and other chemicals 
influenced the current regulation of cosmetics.  Between 1879 and 
1906, dozens of Congressional bills seeking to regulate food and 
drugs had failed to pass.16  The Pure Food and Drugs Act of 1906, 
however, finally authorized the Bureau of Chemistry to prohibit 
adulterated or mislabeled food and drugs.17  Adulterated drugs 
were those whose strength, quality, or purity departed from 
professional standards,18 while misbranded drugs included those 
with misleading or false packaging or labeling.19  “The central 
purpose of the food and drug legislation was to prohibit 
adulteration and misrepresentation.  This perfectly laudable 
objective amounted to little more than a modest extension of the 
common law prohibition against fraudulent conduct.”20 
These early efforts to regulate drugs were often hindered by 
narrow judicial interpretations and high evidentiary burdens.  In 
1911, the Supreme Court of the United States, in United States v. 
Johnson, held that false statements on a drug’s label indicating it 
was effective in curing cancer did not cause the drug to be 
 
 15. Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. §§ 301-399f 
(2012). 
 16. FDA History - Part I: The 1906 Food and Drugs Act and its Enforcement, 
FDA, http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054819.htm 
(last visited Feb. 19, 2014) [hereinafter FDA History]. 
 17. Pure Food and Drugs Act of 1906, Pub. L. No. 59-384, 34 Stat. 768, § 2 
(1906); FDA History, supra note 16.  In 1927, the relevant operations of the 
Bureau of Chemistry were moved to the newly created Food, Drug, and 
Insecticide Administration, later known as the FDA.  Significant Dates in U.S. 
Food and Drug Law History, FDA, http://www.fda.gov/AboutFDA/WhatWeDo/ 
History/Milestones/ucm128305.htm (last visited Feb. 19, 2014). 
 18. Pure Food and Drugs Act § 7. 
 19. Id. § 8. 
 20. Robert L. Rabin, Federal Regulation in Historical Perspective, 38 STAN. L. 
REV. 1189, 1228 (1986). 
5
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mislabeled under the Pure Food and Drugs Act.21  The Court 
noted that “the phrase [mislabeled] is aimed not at all possible 
false statements, but only at such as determine the identity of the 
article, possibly including its strength, quality and purity . . . .”22  
Congress amended the Act in the following year to do an end run 
around Johnson, by specifically prohibiting false therapeutic 
claims for drugs.23 
While the amended Pure Food and Drugs Act provided some 
minimum regulation of drugs, it still had significant 
shortcomings.24  The Amendment attempted to protect consumers 
by allowing prosecution for false therapeutic statements, 
however, the Amendment also required proof that such 
statements were intended to defraud consumers, and thus 
significantly increased the government’s burden to win cases.25 
Additionally, the Act did not require that drugs be proven 
safe or effective prior to distribution.26  As a result, a number of 
 
 21. United States v. Johnson, 221 U.S. 488, 498 (1911). 
 22. Id. at 497.  The Johnson holding that, despite labeling indicating that a 
drug was effective in curing cancer (when it was not so proven), the drug was 
not “misbranded,” appeared to directly conflict with the clear language of the 
Pure Food and Drug Act: “[T]he term ‘misbranded’ . . . shall apply to all drugs, . . 
. the package or label of which shall bear any statement, design, or device 
regarding such article, or the ingredients or substances contained therein which 
shall be false or misleading in any particular . . . .”  Id. (citing Pure Food and 
Drugs Act § 8). 
 23. Sherley Amendment of 1912, 37 Stat. 416 (1912). (A drug shall be 
misbranded “[i]f its package or label shall bear or contain any statement, design, 
or device regarding the curative or therapeutic effect of such article or any of the 
ingredients or substances contained therein, which is false and fraudulent.”). 
 24. See supra notes 17-20 and accompanying text. 
 25. Marc T. Law, How do Regulators Regulate? Enforcement of the Pure Food 
and Drugs Act, 1907-38, 22(2) J.L. ECON. & ORG. 459, 472-73 (2006).  The 
Supreme Court of the United States, in a case construing the meaning of the 
Sherley Amendment of 1912, held that: “it must be found that the statement 
contained in the package was put there to accompany the goods with actual 
intent to deceive,—an intent which may be derived from the facts and 
circumstances, but which must be established.”  Seven Cases v. United States, 
239 U.S. 510, 517 (1916).  But see United States v. 47 Bottles, 200 F. Supp. 1, 6 
(D.N.J. 1961) (interpreting the corresponding mislabeled drug provision of the 
later FDCA and finding that “no fraudulent intent . . . need be shown . . .”). 
 26. See Johnson, 221 U.S. at 496; see also FDA History, supra note 16 (“The 
basis of the [Pure Food and Drugs Act] rested on the regulation of product 
labeling rather than pre-market approval.”). 
6http://digitalcommons.pace.edu/pelr/vol31/iss3/1
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harmful products continued to be sold and consumed.27  The most 
shocking case involved Elixir Sulfanilamide.28  Sulfanilamide 
drugs were used throughout the 1930s without incident, until one 
manufacturer produced a liquid form of the drug dissolved in a 
type of antifreeze.29  Over 100 people died after using the drug, 
and the public pressured Congress to pass the Federal Food, 
Drug, and Cosmetic Act (FDCA) of 1938, which forms the basis of 
all cosmetics regulation in the United States today.30 
b.   The FDCA 
The FDCA of 193831 was intended to address many of the 
problems with the Pure Food and Drugs Act.32  Congress 
specifically included cosmetics within the new FDCA, partly in 
response to the FDA’s publicizing of many defective and harmful 
cosmetic products prior to the bill’s passage.33  The FDCA 
explicitly banned misbranded or adulterated cosmetics.34  
Adulterated cosmetics under the Act include: 
[1] [Cosmetics] that [bear] or [contain] any poisonous or 
deleterious substance which may render it injurious to users 
 
 27. See Patricia I. Carter, Federal Regulation of Pharmaceuticals in the 
United States and Canada, 21 LOY. L.A. INT’L & COMP. L.J. 215, 217-18 (1999). 
 28. See id. at 218. 
 29. Id. 
 30. Id. 
 31. See 21 U.S.C. §§ 301-399f. 
 32. See David F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its 
Legislative History and Its Substantive Provisions, 6 LAW & CONTEMP. PROBS. 2, 
12-13 (1939). 
 33. See FDA History Part II: The 1938 Food, Drug, and Cosmetic Act, FDA, 
http://www.fda.gov/aboutFDA/WhatWeDo/History/origin/ucm054826.htm (last 
visited Feb. 19, 2014) (“The FDA . . . [assembled] a collection of products that 
illustrated shortcomings in the [Pure Food and Drug Act].  It included . . . Lash-
Lure, an eyelash dye in which a number of women suffered injuries to their 
eyes, including one confirmed case of permanent blindness . . . .”). 
 34. 21 U.S.C. § 331(a).  “Cosmetic” is defined as: 
(1) articles intended to be rubbed, poured, sprinkled, or sprayed on, 
introduced into, or otherwise applied to the human body or any part 
thereof for cleansing, beautifying, promoting attractiveness, or 
altering the appearance, and (2) articles intended for use as a 
component of any such articles; except that such term shall not 
include soap. 
Id. § 321(i). 
7
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under the conditions of use prescribed in the labeling thereof, or 
under such conditions of use as are customary or usual; . . . [2] 
[cosmetics consisting] in whole or in part of any filthy, putrid, or 
decomposed substance; . . . [3] [cosmetics made or held] under 
insanitary conditions whereby [they] may have become 
contaminated with filth, or whereby [they] may have been 
rendered injurious to health, . . . [4] [and cosmetics with a] 
container composed, in whole or in part, of any poisonous or 
deleterious substance which may render the contents injurious to 
health . . . .35 
A cosmetic product can also be “misbranded” under the FDCA if: 
(1) its labeling is false or misleading; (2) its label does not contain 
the name and address of the manufacturer, packer, or distributor, 
or an accurate ingredient list; or (3) if “any word, statement, or 
other information required by . . . this [Act] to appear on the label 
. . . is not prominently placed thereon . . . in such terms as to 
render it likely to be read and understood by the ordinary 
individual under customary conditions of purchase and use.”36 
These statutory definitions of “misbranded” and 
“adulterated” remain in place today, although originally enacted 
in 1938,37 and even as we have made vast strides in our scientific 
and technological knowledge in the last century.38  The statutory 
nomenclature speaks of “putrid” and “filthy” products made under 
unsanitary conditions, evincing a lack of understanding of 
current corporate production, and a total lack of concern about 
the long-term effects of a cosmetic product on the user.39  Instead, 
the FDCA was then and continues today to be mainly concerned 
with the immediate and short-term effects of a consumer product 
and its ingredients.  By these standards, most cosmetic products 
are considered safe in the United States today, absent some 
meaningful proof of harm in the long-term, which is not regularly 
available.40 
 
 35. Id. § 361(a)-(d). 
 36. Id. § 362(a)-(c). 
 37. 21 U.S.C. §§ 361, 362. 
 38. WHO WILL KEEP THE PUBLIC HEALTHY? EDUCATING PUBLIC HEALTH 
PROFESSIONALS FOR THE 21ST CENTURY 27 (Kristine Gebbie et al. eds., 2003), 
available at http://www.nap.edu/openbook.php?isbn= 030908542X. 
 39. See 21 U.S.C. § 361(b)-(c). 
 40. See Mary O’Brien, Our Current Toxics Use Framework, Our Stolen 
Future, and Our Options, 11 J. ENVTL. L. & LITIG. 331, 346-51 (1996) (reviewing 
8http://digitalcommons.pace.edu/pelr/vol31/iss3/1
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c.  Recent Changes to the FDCA 
 While the FDCA remains largely similar to the original 
statute, several recent changes deserve note.  Under the FDCA, 
labeling requirements include specific warning labels for coal-tar 
hair dye,41 in addition to the general prohibitions on false or 
misleading labels or packaging, exclusive of ingredient lists.42  
The Fair Packaging and Labeling Act43 also contains provisions 
requiring product labels to conspicuously include information 
about the manufacturer, packer or distributor, and net quantity 
information.44  The Special Packaging of Household Substances 
for Protection of Children Act, commonly known as the Poison 
Prevention Packaging Act of 1970,45 allows the Consumer 
Product Safety Commission to set special packaging guidelines 
for consumer products that may have a high degree of risk to 
children.46  Specific labeling and packaging requirements also 
attach under FDA regulations within the existing legal 
framework.47  An amendment to the FDCA in 1997 also 
outlawed—with minor exceptions—any state or local 
requirements for labeling or packaging of cosmetics that are 
different from requirements under the Act, the Poison Prevention 
Packaging Act of 1970, or the Fair Packaging and Labeling Act.48   
In July 2012, as part of an effort to extend current FDA user-
fee programs and to institute new fees, Congress also added a 
section on “nanotechnology” to the FDCA.49  “Nanotechnology,” 
“nanomaterials,” and “nanoparticles” all refer to new materials 
 
THEO COLBORN ET AL., OUR STOLEN FUTURE: ARE WE THREATENING OUR 
FERTILITY, INTELLIGENCE, AND SURVIVAL?—A SCIENTIFIC DETECTIVE STORY 
(1996)). 
 41. 21 U.S.C. § 361(a). 
 42. Id. § 362(a). 
 43. Fair Packaging and Labeling Program, 15 U.S.C. §§ 1451-1461 (2012). 
 44. Id. § 1453(a)(1)-(2). 
 45. Special Packaging of Household Substances for Protection of Children, 15 
U.S.C. §§ 1471-1477 (2012). 
 46. See id. § 1472(a)(1). 
 47. See generally 21 C.F.R. §§ 701.1-701.30 (2014) (FDA regulations for 
cosmetic labeling); 16 C.F.R. §§ 500.1-500.29 (2014) (Federal Trade Commission 
regulations under section 4 of the Fair Packaging and Labeling Act); 16 C.F.R. 
§§ 1700.1-1700.20 (2014) (Consumer Product Safety Commission regulations 
under the Poison Prevention Packaging Act of 1970). 
 48. 21 U.S.C. § 379s(a). 
 49. See id. § 399e. 
9
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created from the manipulation of atoms and molecules at the 
“nanometer scale,” that is, from 1 nanometer to 100 
nanometers.50  The use of such nanoparticles in cosmetic products 
in recent years has increased dramatically, often because these 
new materials have new or enhanced properties, including “color, 
transparency, solubility[,] and chemical reactivity . . . .”51  Certain 
nanoparticles, however, have been found to have high risks of 
health concerns, often because the very small size of the particles 
increases the likelihood of inhalation or migration beyond the 
surface of the skin.52  Furthermore, their small size is believed to 
increase the possibility that they might interact with more 
sensitive cells of the body,53 such as in the digestive tract or 
respiratory system. 
This new section in the FDCA attempts to address these 
concerns by authorizing the FDA to “intensify and expand 
activities related to enhancing scientific knowledge regarding 
nanomaterials” intended for use in products regulated by the 
FDA, and to collect user fees to further this purpose.54  The 
section notes that these new studies will address issues including 
“the potential toxicology of such nanomaterials, the potential 
benefit of new therapies derived from nanotechnology, the effects 
of such nanomaterials on biological systems, and the interaction 
of such nanomaterials with biological systems.”55 
B.  Cosmetic Ingredient Review and Industry Self-
Regulation 
The cosmetics industry has over the last forty years also 
made a minimal attempt to self-regulate.  The Cosmetic 
Ingredient Review Panel (CIR) was established in 1976 by the 
cosmetic industry’s trade association,56 and is also funded by that 
 
 50. Raj Silpa et al., Nanotechnology in Cosmetics: Opportunities and 
Challenges, 4 J. PHARMACY & BIOALLIED SCI. 186, 186 (2012) (noting that one 
nanometer is one billionth of a meter). 
 51. Id. 
 52. Id. at 188. 
 53. See Silpa et al., supra note 50, at 188. 
 54. 21 U.S.C. § 399e(a). 
 55. Id. 
 56. About the Cosmetic Ingredient Review, COSMETIC INGREDIENT REV., 
http://www.cir-safety.org/about (last visited Feb. 20, 2014) (The CIR was set up 
10http://digitalcommons.pace.edu/pelr/vol31/iss3/1
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association.57  The CIR assesses the safety of ingredients used in 
cosmetic products.58  Voting panel members include doctors and 
scientists, plus three non-voting members representing the 
cosmetics industry, consumer groups, and the government.59 
The importance of the CIR’s findings to FDA determinations 
regarding the safety of cosmetic products is revealed in references 
to the expert panel’s evaluations in a number of the FDA’s 
rulemaking notices.60  The EPA61 and the Occupational Safety 
and Health Administration62 have also referenced CIR studies in 
their respective actions.  The FDA has nonetheless noted, that 
CIR determinations do not serve as the sole source of evidence for 
rulemaking actions regarding cosmetics.63 
While CIR review is a laudable and ambitious program of 
self-regulation, experts have estimated that only between 11% 
and 13% of ingredients used in cosmetics have actually been 
subject to CIR analysis.64  Additionally, the CIR has only found 
 
and is funded by what was the Cosmetic, Toiletry, and Fragrance Association, 
now the Personal Care Products Council, with the support of the FDA and the 
Consumer Federation of America.). 
 57. Id. 
 58. How Does CIR Work?, COSMETIC INGREDIENT REV., http://www.cir-safety. 
org/how-does-cir-work (last visited Feb. 20, 2014). 
 59. Id. 
 60. See, e.g., 50 Fed. Reg. 39,854 (Sept. 30, 1985) (notice of proposed 
rulemaking regarding dental anti-cavity products); 70 Fed. Reg. 1721, (Jan. 10, 
2005) (guidance for industry regarding cosmetic products containing alpha 
hydroxy acids); 68 Fed. Reg. 32,232 (May 29, 2003) (notice of proposed 
rulemaking regarding anti-plaque and anti-gingivitis products). 
 61. See, e.g., 54 Fed. Reg. 8116 (Feb. 24, 1989) (notice of intent to cancel 
regulations for pesticides containing captan); 60 Fed. Reg. 54,637 (Oct. 25, 1995) 
(proposed rule regarding jojoba oil); 76 Fed. Reg. 56,644 (Sept. 14, 2011) (notice 
of final rule regarding sulfur dioxide). 
 62. See, e.g., 52 Fed. Reg. 46,168 (Dec. 4, 1987) (final rule regarding 
occupational exposure to formaldehyde). 
 63. 58 Fed. Reg. 33,700 (June 8, 1993).  The FDA noted that 
[t]hese [CIR] reviews are used primarily by industry to make self-
determinations of cosmetic ingredient safety.  The agency may, or 
may not, comment on any CIR.  Even where FDA comments on a 
CIR, there would be little likelihood that agency rulemaking would 
result.  In situations where such a review does serve as a stimulus 
for a rulemaking proceeding, the review would not be the sole reason 
for the proceeding. 
Id. 
 64. See Rajiv Shah & Kelly E. Taylor, Concealing Danger: How the 
Regulation of Cosmetics in the United States Puts Consumers at Risk, 23 
11
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eleven chemicals or groups of chemicals actually unsafe for use in 
cosmetics since the panel first came into existence almost forty 
years ago.65  Moreover, manufacturers are not even required to 
follow CIR’s published determinations.66  In California’s recently 
enacted laws regulating cosmetic products,67 the statement of 
legislative findings notes that “54 cosmetic products violate the 
CIR’s own safe use recommendations to manufacturers by 
containing an ingredient that the CIR has found is not safe for 
the specific use indicated on the product’s label.”68  There have 
also been instances where CIR determinations of a substance’s 
safety directly conflict with other findings of significant health 
concerns.69 
C.  Lack of Regulation of Endocrine Disruptors in 
Cosmetics70 
One significant health concern is chemicals that disrupt or 
have the potential to disrupt the human endocrine system.  These 
so-called endocrine disrupting chemicals (EDCs) are synthetic 
compounds71 found routinely in cosmetic products.72  Yet, EDCs 
 
FORDHAM ENVTL. L. REV. 203, 204 (2012); Katharine A. Van Tassel & Rose H. 
Goldman, The Growing Consumer Exposure to Nanotechnology in Everyday 
Products: Regulating Innovative Technologies in Light of Lessons from the Past, 
44 CONN. L. REV. 481, 511 (2011). 
 65. Myths on Cosmetics Safety, EWG'S SKIN DEEP, http://www.ewg.org/ 
skindeep/myths-on-cosmetics-safety/ (last visited Feb. 20, 2014). 
 66. See Sarah E. Schaffer, Reading Our Lips: The History of Lipstick 
Regulation in Western Seats of Power, 62 FOOD & DRUG L.J. 165, 200 (2007). 
 67. California’s progressive and health protective cosmetics laws, known as 
California’s Safe Cosmetics Act of 2005, are discussed in further in Part IV.D of 
this article.  See infra notes 269-74 and accompanying text. 
 68. CAL. HEALTH & SAFETY CODE § 111793.5(a)(2) (West 2014). 
 69. See, e.g., Thomas O. McGarity, Resisting Regulation with Blue Ribbon 
Panels, 33 FORDHAM URB. L.J. 1157, 1190 (2006). 
 70. This section is reprinted in part with permission and is originally found 
in-part at: Valerie J. Watnick, Our Toxics Regulatory System and Why Risk 
Assessment Does Not Work: Endocrine Disrupting Chemicals as a Case in Point, 
2004 UTAH L. REV. 1305, 1307-10 (2004). 
 71. Cassandra L. Bevan et al., The Effects of Endocrine Disrupting 
Compounds on the Development of the Nervous System: Use of the Frog, Xenopus 
Laevis, as a Model System, 2 VT. J. ENVTL. L. 41, 42 (2001). 
 72. See, e.g., Rachael Rawlins, Teething on Toxins: In Search of Regulatory 
Solutions for Toys and Cosmetics, 20 FORDHAM ENVTL. L. REV. 1, 3 (2009) 
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are believed by scientists to be one of the most significant man-
made environmental problems of our time.73  EDCs affect the 
functioning of the endocrine system74 by either blocking the effect 
of naturally produced hormones in the endocrine system or by 
altering the effect of naturally occurring hormones.75  The 
inherent difficulty in regulating EDCs to achieve safety, or what 
might be called negligible,76 or politically acceptable risk,77 is 
that the science of endocrine disruption remains relatively new.78  
 
(referring to findings of “personal-care products containing known or suspected 
endocrine-disrupting chemicals”). 
 73. See generally THEO COLBORN ET AL., OUR STOLEN FUTURE: ARE WE 
THREATENING OUR FERTILITY, INTELLIGENCE, AND SURVIVAL?—A SCIENTIFIC 
DETECTIVE STORY (1996). 
 74. What Are Endocrine Disrupters?, EPA, http://www.epa.gov/scipoly/ 
oscpendo/pubs/edspoverview/whatare.htm (last visited Feb. 20, 2014) (“The 
endocrine system regulates all biological processes in the body from conception 
through adulthood and into old age, including the development of the brain and 
nervous system, [and] the growth and function of the reproductive system . . . .”). 
 75. O’Brien, supra note 40, at 333.  The endocrine system consists of glands, 
organs, and tissues that release hormones into the human circulatory system.  
The hormones carry messages that direct development and function in the 
animal’s cells and organs.  Hormones therefore control sexual development, both 
prenatally and postnatally.  Id. at 332.  Commonly known EDCs include various 
pesticides, polychlorinated biphenyls (PCBs), and dioxins (a byproduct of paper 
production).  Robin Fastenau, EPA’s Investigation and Regulation of Endocrine 
Disruptors, 14 J. ENVTL. L. & LITIG. 53, 54 (1999). 
 76. Negligible risk is commonly considered to be the one-in-a-million chance 
that an event will occur.  While this seems like a small amount of risk, it takes 
on a new meaning when you or someone you love is the one suffering the harm.  
Additionally, these sorts of risk calculations do not account for the fact that a 
typical consumer faces accumulated negligible risks from multiple toxic sources 
every day.  Watnick, supra note 68, at 1306 n. 8. 
 77. Id. 
 78. See, e.g., Jonathan Chevrier et al., Maternal Urinary Bisphenol A during 
Pregnancy and Maternal and Neonatal Thyroid Function in the CHAMACOS 
Study, 121 ENVTL. HEALTH PERSP. 138, 138-39 (2012), available at http://ehp. 
niehs.nih.gov/wp-content/uploads/121/1/ehp.1205092.pdf; Fastenau, supra note 
75, at 54-56 (explaining that in 1999, the EPA was entering a new phase in the 
regulation of toxics by becoming more concerned about the effects of chemicals 
that could potentially affect the human endocrine system as a result of the 
passage of the Food Quality Protection Act of 1996 and amendments to the Safe 
Drinking Water Act); Endocrine Disruptors, NAT'L INST. OF ENVTL. HEALTH SCI., 
http://www.niehs.nih.gov/health/materials/endocrine_disruptors_508.pdf#search
=endocrine (last visited Feb. 20, 2014) [hereinafter Endocrine Disruptors].  See 
Safe Drinking Water Act, 42 U.S.C. §§ 300f-300j-26 (2012); Food Quality 
Protection Act of 1996, Pub. L. No. 104-170, 110 Stat. 1489 (codified as amended 
at various sections of 7 U.S.C. and 21 U.SC.).  The EPA has stated that for the 
majority of chemicals, it does not have either effects or toxicity data with regard 
13
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EDCs are believed to work by blocking the effect of hormones or 
by mimicking hormones so that the organism’s reactions are 
altered.79  They are believed to “engage with the body’s 
mechanism for regulating growth and development, while 
sabotaging its normal functions.”80  Synthetic chemicals that act 
like hormones may bind to hormone receptors just as natural 
hormones would, but then interfere with the intended bodily 
function.81  Alternatively, EDCs may relay molecular messages 
that alter cell growth and division.82 
While the exact mechanism by which EDCs cause harm is 
not fully understood,83 the potential harm from EDCs is 
insidious84 and well documented.85  In particular, scientists have 
hypothesized that a link exists between EDCs and decreased 
 
to endocrine disruption.  67 Fed. Reg. 79,611, 79,614 (Dec. 30, 2002).  Even as to 
the risk of cancer, which has been studied for many years, at least two 
commentators have suggested that the use of risk analysis to draw conclusions 
about cancer occurrence is limited, and subject to the application of a myriad of 
estimates and assumptions.  John S. Applegate & Celia Campbell-Mohn, Risk 
Assessment: Science, Law and Policy, 14 NAT. RES. & ENV'T 219, 220-21 (2000). 
 79. O’Brien, supra note 40, at 339. 
 80. Sheldon Krimsky, A Clue to Understanding the Environmental Causes of 
Disease, 43 ENV'T 22, 26-27 (2001), available at www.tufts.edu/~skrimsky/PDF/ 
environ.PDF. 
 81. See Krimsky, supra note 80, at 27. 
 82. Id. 
 83. JOHN WARGO, OUR CHILDREN’S TOXIC LEGACY: HOW SCIENCE AND LAW FAIL 
TO PROTECT US FROM PESTICIDES 12 (1998) (noting that certain chemicals may 
act as endocrine disrupters, but that the precise nature by which endocrine 
disrupters operate is not known); Noah Sachs, Blocked Pathways: Potential 
Legal Responses to Endocrine Disrupting Chemicals, 24 COLUM. J. ENVTL. L. 289, 
290, 300 (1999) (noting that because the science of endocrine disruption is 
relatively new, further research into the causal mechanism is required); see also 
Leticia M. Diaz, Hormone Replacement Therapy, or Just Eat More Meat: The 
Technological Hare vs. the Regulatory Tortoise, 27 B.C. ENVTL. AFF. L. REV. 391, 
416 (2000). 
 84. See, e.g., Karen Fassuliotis, Comment, The Science of Endocrine 
Disruption—Will it Change the Scope of Products Liability Claims?, 17 PACE 
ENVTL. L. REV. 351, 357-60 (2000) (noting that EDCs may be a factor in 
increasing rates of breast cancer, adverse reproductive trends, and decreased 
functioning of the nervous system and the immune system); Phil Zahodiakin, 
Hexachlorobenzene Linked to Androgen Disruption, PESTICIDE & TOXIC CHEM. 
NEWS (Feb. 17, 2003) (noting that hexachlorobenzene, a known hormone 
disrupter and herbicide now banned in the United States, is believed to be 
present in over 95% of the U.S. population, and has adverse effects on ovarian 
function). 
 85. See infra notes 87-88 and accompanying text. 
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sperm counts, breast, testicular and prostate cancers, and 
neurological disorders.86  Even more unsettling is that EDCs are 
omni-present in everyday cosmetic products, in addition to 
household products,87 food and beverage containers, household 
pesticides, and pesticide residues on food.88 
Yet, the current cosmetics regulation system in the United 
States is silent on the issue of EDCs despite the fact that federal 
law has begun to recognize the danger of EDCs, and in certain 
areas, authorizes federal agencies to consider potential endocrine 
health effects.89  The Safe Drinking Water Act, for example, 
designed to improve the safety of our nation’s drinking water, 
contains a general provision, which allows the EPA to regulate 
where it believes a substantial population might be exposed to an 
EDC.90  Likewise, the Toxic Substances Control Act allows the 
EPA to regulate a chemical substance or mixture that presents an 
“unreasonable risk of injury to health or the environment.”91  
Conceivably, this statute could be used to regulate and protect 
consumers from EDCs in cosmetics, but the reality is that the 
 
 86. Krimsky, supra note 80, at 22. 
 87. See generally SANDRA STEINGRABER, LIVING DOWNSTREAM: AN ECOLOGIST’S 
PERSONAL INVESTIGATION OF CANCER AND THE ENVIRONMENT, 113-14, 277-78 
(2010) (giving an overview of EDCs, and urging that EDCs are related to the 
development of cancer, noting that phthalates, a “ubiquitous class of 
petrochemicals” and a “leading suspect[] in this ransacking of manhood” are 
commonly used in cosmetics). 
 88. Chemicals that are suspected of having adverse effects on the endocrine 
system are ubiquitous.  They include: tributylin, found in paint; flame 
retardants used in furniture, carpet, and electronic products; bisphenol-A, a 
chemical used in the lining of food and beverage containers; phthalates, found in 
plastics; pesticides; chemicals found in cosmetics; and alkyl phenols, used in 
detergents.  Additionally, hormone disrupting chemicals are produced when 
paper is made, and in other combustion and industrial processes.  These 
chemicals are found in our air, and seep into our drinking water.  Controversial 
Issues, ENDOCRINE/ESTROGEN LETTER, http://www.eeletter.com/cntrvrsl/index. 
html (last visited Feb. 20, 2014); see also, Erin Gill, Cleaning Your Home Can 
Make You Ill, THE EVENING STANDARD, Nov. 25, 2003, at A26 (noting that 
everyday items such as electrical goods, nonstick frying pans, and sofa and foam 
seating contain chemicals that are under suspicion for endocrine disruption).  
Chemicals such as PCBs, organochlorine pesticides, and brominated flame 
retardants have been linked to rising rates of breast cancer, testicular cancer, 
and asthma.  Id. 
 89. See infra notes 90-96 and accompanying text. 
 90. 42 U.S.C. § 300j-17. 
 91. 15 U.S.C. § 2601(b)(2) (2012). 
15
  
610 PACE ENVIRONMENTAL LAW REVIEW [Vol.  31 
EPA has infrequently used the Toxic Substances Control Act to 
protect human health since its passage in 1976.92 
The Food Quality Protection Act of 1996 (FQPA), often called 
landmark legislation aimed at making our overall U.S. food 
system safer, and amending the FDCA, specifically called for an 
Estrogenic Substances Screening Program, commonly known as 
the Endocrine Disruptor Screening Program (EDSP), to analyze 
whether chemicals may have endocrine effects on humans.93  Yet, 
the FQPA has not lived up to its overall promise, its promise as to 
potential EDCs, or its promise to protect children.94  The EDSP 
called for by the 1996 Act, has had little effect on how we regulate 
potential EDCs in the food arena.95  More than a decade after the 
passage of the FQPA, calling for an identification and assessment 
of EDCs in food, the EDSP had not designated a single chemical 
as an EDC.96 
The FQPA requires the EPA to use Quantitative Risk 
Assessment (QRA) to regulate chemicals suspected EDCs.  QRA 
is the process of characterizing the “potential adverse health 
effects of human exposures to environmental hazards.”97  QRA 
 
 92. Holly E. Pettit, Shifting the Experiment to the Lab: Does EPA Have a 
Mandatory Duty to Require Chemical Testing for Endocrine Disruption Effects 
Under the Toxic Substances Control Act?, 30 ENVTL. L. 413, 424 (2000). 
 93. 21 U.S.C. § 346a(p). 
 94. See Kristina Thayer & Jane Houlihan, Pesticides, Human Health, and the 
Food Quality Protection Act, 28 WM. & MARY ENVTL. L. & POL’Y REV. 257, 291-
303 (2004). 
 95. See EPA, OFFICE OF INSPECTOR GEN., REPORT NO. 11-P-0215, EPA’S 
ENDOCRINE DISRUPTOR SCREENING PROGRAM SHOULD ESTABLISH MANAGEMENT 
CONTROLS TO ENSURE MORE TIMELY RESULTS 9-19 (2011) [hereinafter REPORT 
NO. 11-P-0215]. 
 96. Id. at iii.  As of 2011, EDSP had not formulated the Program’s goals and 
priorities, or established measures to track program results.  Id.  Additionally, 
the EDSP missed required deadlines to validate assays and to select chemicals 
for priority evaluation.  Id.; see also Natural Res. Def. Council v. Whitman, No. 
C 99-03701 WHA, 2001 WL 1221774, at *1 (N.D. Cal. Sept. 24, 2001).  The 2001 
consent decree between the Natural Resources Defense Council and the EPA 
required the EPA to prioritize chemicals for screening and evaluation, and to do 
an initial “Tier I” screening of the 87,000 chemicals on the market that have the 
potential for endocrine effects.  Id. at 21-22; 63 Fed. Reg. 42,852, 42,854 (Aug. 
11, 1998). 
 97. NAT’L RESEARCH COUNCIL, RISK ASSESSMENT IN THE FEDERAL 
GOVERNMENT: MANAGING THE PROCESS 18 (1983) (commonly referred to as the 
“Redbook”); see Valerie Watnick, Risk Assessment: Obfuscation of Policy 
Decisions in Pesticide Regulation and the EPA’s Dismantling of the Food Quality 
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appears to be a good idea on its face—a purely objective and 
scientific analysis to ferret out substances that may present a 
risk to human health.  However, the QRA process has been 
subject to serious criticism by scholars and policy makers,98 
urging that the many assumptions and extrapolations involved in 
risk assessments are keenly influenced by a decision maker’s 
personal and political point of view.99  Risk assessment 
determinations may be based on a “mixture of fact, experience 
(often called intuition), and personal values that cannot be 
disentangled easily.”100  Changing assumptions can result in a 
risk assessment that is either more or less protective of human 
health.101  An additional major limitation cited regarding QRA is 
the “limited analytic resources” available to recognize and 
evaluate potentially dangerous substances.102 
Yet, despite the many shortcomings of QRA, there is an 
argument that if a federal statute at least calls for an assessment 
of risk, there begins a public recognition of some potential for risk 
to humans.103  In the cosmetics arena, as discussed further below, 
federal regulation does not even require identification of risk in 
any serious manner, let alone risk assessment with regard to 
 
Protection Act’s Safeguards for Children, 31 ARIZ. ST. L.J. 1315, 1332-36 (1999) 
(giving a thorough discussion of QRA). 
 98. See, e.g., Junius C. McElveen, Jr. & Chris Amantea, Legislating Risk 
Assessment, 63 U. CIN. L. REV. 1553, 1579 (1995) (noting shortcomings in the 
risk assessment process, and concluding it overstates risk and provides no 
additional protection); Mark Eliot Shere, The Myth of Meaningful 
Environmental Risk Assessment, 19 HARV. ENVTL. L. REV. 409, 421 (1995) 
(addressing the “unreliability and malleability” of risk assessments); Wendy E. 
Wagner, The Science Charade in Toxic Risk Regulation, 95 COLUM. L. REV. 1613, 
1625 (1995) (analyzing the complex mix of policy and science in risk assessment 
decision making). 
 99. See Staci Jeanne Krupp, Environmental Hazards: Assessing the Risk to 
Women, 12 FORDHAM ENVTL. L.J. 111, 123-24 (2000) (arguing that risk 
assessments are inherently “value-laden”). 
 100. NAT’L RESEARCH COUNCIL, supra note 97, at 36. 
 101. See id. at 37. 
 102. See id. at 12. 
 103. See Jeff Gimpel, Note, The Risk Assessment and Cost Benefit Act of 1995: 
Regulatory Reform and the Legislation of Science, 23 J. LEGIS. 61, 72 (1997) 
(“Hazard identification is the first phase in the process of assessing risk.  This 
requires identifying the agent in the environment which may cause harm and 
assessing the evidence which associates exposure to the agent with the resulting 
harm.”). 
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personal care and cosmetic product ingredients.104  Cosmetics law 
in the United States instead allows manufacturers to simply state 
that existing research shows that the product or ingredient is safe 
to use, or to issue a statement that no determination regarding 
safety has been made.105 
 
 
 
II.  THE DANGER OF EDCS AND CARCINOGENIC 
SUBSTANCES IN COSMETICS, THE UNIQUE 
DANGER TO CHILDREN, AND THE NEED TO 
REGULATE TO PROTECT AGAINST THESE 
POTENTIAL HARMS 
A.  The “True Burden” of Environmental Cancers is 
Understated and the Specific Need to Reduce Toxic 
Exposure for Children 
In 2010, the President’s Cancer Panel issued a 
groundbreaking report, asserting that the “true burden of 
environmentally induced cancer has been grossly 
underestimated.”106  The report specifically encouraged 
consumers to eat food that is not grown with synthetic pesticides, 
chemical fertilizers, and growth hormones, to reduce the risk of 
contracting cancer.107  The World Health Organization has 
likewise estimated that by 2020, the overall rate of cancer in the 
 
 104. See supra notes 31-69 and accompanying text. 
 105. Id. 
 106. LaSalle D. Leffall, Jr. & Margaret L. Kripke, Letter to the President in 
SUZANNE H. REUBEN, PRESIDENT’S CANCER PANEL, REDUCING ENVIRONMENTAL 
CANCER RISK: WHAT WE CAN DO NOW (2010), available at http://deainfo.nci. 
nih.gov/advisory/pcp/annualReports/pcp08-09rpt/PCP_Report_08-09_508.pdf 
[hereinafter Letter to the President]. 
 107. SUZANNE H. REUBEN, PRESIDENT’S CANCER PANEL, REDUCING 
ENVIRONMENTAL CANCER RISK: WHAT WE CAN DO NOW xx (2010), available at 
http://deainfo.nci.nih.gov/advisory/pcp/annualReports/pcp08-09rpt/PCP_Report_ 
08-09_508.pdf. 
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developing world will increase by 73%, and in the developed 
world by 29%.108 
In particular, the President’s Cancer Panel’s report also 
stressed the need to reduce toxic exposure for children.109  This 
report was followed by documentation in the highly respected 
journal, Pediatrics, which concluded that exposure to 
organophosphate pesticides, commonly used on food in the United 
States,110 may be contributing to the development of Attention 
Deficit Hyperactivity Disorder in children in the United States.111 
These findings regarding the specific concerns for children 
came as no real surprise as the National Research Council 
reported, as early as 1993, that children are intrinsically more 
susceptible to harm from environmental toxins.112  The National 
Research Council found that physiological and biochemical 
differences between adults and children make children more 
susceptible to the specific effects of pesticides in the 
environment.113  Experts subsequently concluded that because 
they take in more air, food, and water per pound of body weight, 
and because their physical bodies are still developing, children 
are more susceptible generally to the effects of toxic substances in 
the environment.114  And yet, two decades later, the vast majority 
of our regulation of environmental toxins, including the 
regulation of deleterious substances in cosmetics, does not treat 
children and adults differently or even begin to address these 
 
 108. WORLD HEALTH ORG. & FOOD & AGRIC. ORG., DIET, NUTRITION AND THE 
PREVENTION OF CHRONIC DISEASES 95 (2003), available at http://whqlibdoc.  
who.int/trs/who_trs_916.pdf. 
 109. REUBEN, supra note 107, at xix. 
 110. Maryse F. Bouchard et al., Attention-Deficit/Hyperactivity Disorder and 
Urinary Metabolites of Organophosphate Pesticides, 125 PEDIATRICS 1270, 1271 
(2010), available at http://pediatrics.aappublications.org/content/early/2010/05/ 
17/peds.2009-3058.full.pdf+html; see Organophosphates, PESTICIDE ACTION 
NETWORK, http://www.panna.org/resources/organophosphates (last visited Feb. 
20, 2014) (noting that organophosphates are the most heavily used in the United 
States, are toxic to the human nervous system, and are thought to be related to 
the declining frog populations in California). 
 111. Bouchard et al., supra note 110, at 1270. 
 112. NAT’L RESEARCH COUNCIL, PESTICIDES IN THE DIETS OF INFANTS AND 
CHILDREN 42-43 (1993). 
 113. See id. at 38, 42-43. 
 114. Cynthia F. Bearer, Environmental Health Hazards: How Children Are 
Different from Adults, 5 THE FUTURE OF CHILD. 11, 11, 15, 18 (1995). 
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widely acknowledged truths.115  Indeed, the FQPA is the only 
federal statute to date to explicitly recognize the “unique 
vulnerabilit[y]” of children to toxins in the environment.116 
B.  The Particular Danger in Failing to Regulate EDCs in 
Cosmetics 
EDCs are believed to have caused decreased fertility rates in 
wildlife, and there is strong evidence that they are having a 
similar effect on humans.117  Perhaps the most infamously known 
case of the effects an EDC on humans involves diethylstilbestrol 
(DES), a synthetic hormone with anti-androgenizing or 
demasculinizing qualities,118 given to pregnant women from the 
1940s to the 1970s to prevent miscarriage.119  DES did not just 
affect the women taking the drug; it had multigenerational 
effects, affecting her unborn fetus’ later health as an adult.120  
Doctors learned that females born to mothers who were given 
DES suffered reproductive abnormalities.121  These women were 
also prone to a rare type of vaginal cancer.122  Additionally, males 
born to mothers to whom DES was administered also suffered 
reproductive abnormalities such as genital malformation and 
other testicular problems.123  Our experience with DES has 
 
 115. See Philip Landrigan, HARV. SCH. OF PUB. HEALTH, http://www.hsph. 
harvard.edu/faculty/philip-landrigan/ (last visited Feb. 20, 2014).  The FQPA 
began to address this different risk for children with regard to pesticide residues 
on food by requiring increased safety mechanisms for children, including the 
requirement that a special ten-times factor be applied in setting a pesticide 
tolerance or limit, unless reliable evidence suggests that the existing standard 
will be safe for children.  21 U.S.C. § 346a(b)(2)(C)(ii). 
 116. Philip Landrigan, supra note 115. 
 117. See COLBORN, ET AL., supra note 73, at 1-9; Keith J. Jones, Endocrine 
Disrupters and Risk Assessment: Potential for a Big Mistake, 17 VILL. ENVTL. 
L.J. 357, 366-67 (2006); Endocrine Disruptors, supra note 78. 
 118. Sachs, supra note 83, at 298. 
 119. Id., at 298-99; see National Environmental Health Association Position on 
Endocrine Disrupters, NAT’L ENVTL. HEALTH ASSOC. (July 2, 1997), http://www. 
neha.org/position_papers/PositionEndocrine.html [hereinafter NEHA Position 
on EDCs]. 
 120. Sachs, supra note 83, at 299. 
 121. Id. 
 122. Id.  The rare form of cancer that afflicts females born to mothers who took 
DES while pregnant is called clear-cell adenocarcinoma.  Id. 
 123. Id.  In the aftermath of the DES era, offspring of mothers who were 
prescribed DES filed lawsuits against the manufacturers of the drug.  Id.  These 
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proven that exposure to EDCs can have profound and lasting 
effects on the human race. 
And yet, without adequate regulation, EDCs are routinely 
used in the formulation of cosmetic consumer products.124  
Triclosan, for example, a chemical commonly found in hand soaps 
touted to be antibacterial,125 and even in toothpastes, has been 
shown to disrupt the human endocrine system.126  Additionally, 
studies have shown that Triclosan affects human breast tissue.127 
Another commonly found chemical in cosmetics is 
oxybenzone.128  Oxybenzone, routinely used in sunscreen 
products because it is believed to block ultraviolet rays, is also 
believed to be an EDC.129  Public interest groups have urged that 
despite its omnipresence in sunscreens, oxybenzone may cause 
hormone disruption, allergies, and may actually contribute to 
some skin cancers.130 
Similarly, another common group of potential EDCs found in 
cosmetics is the paraben group.131  Parabens, often used to 
preserve product shelf life, are used in all sorts of cosmetics, from 
 
lawsuits have resulted in the imposition of liability on manufacturers under a 
market sharing theory.  Id. at 334. 
 124. See Rawlins, supra note 72, at 1. 
 125. Triclosan: What Consumers Should Know, FDA, http://www.fda.gov/ 
forconsumers/consumerupdates/ucm205999.htm (last visited Feb. 20, 2014) 
[hereinafter Triclosan].  Triclosan is also found in toothpaste, which is 
worrisome since we put this directly into our mouths.  Id. 
 126. See Triclosan, supra note 125.  The FDA has not said that the use of a 
soap containing Triclosan is any more beneficial to consumers than ordinary 
soap and water.  Id. 
 127. Triclosan and Triclocarbon, BREAST CANCER FUND, http://www. 
breastcancerfund.org/clear-science/chemicals-glossary/triclosan.html (last 
visited Feb. 20, 2014). 
 128. Is Your Sunscreen in EWG’s Sunscreen Hall of Shame?, ENVTL. WORKING 
GRP. (June 22, 2010), http://www.ewg.org/enviroblog/2010/06/your-sunscreen-
ewgs-sunscreen-hall-shame [hereinafter EWG’s Sunscreen Hall of Shame]. 
 129. Tara Parker-Pope, Sunscreen Safety is Called into Question, N.Y. TIMES, 
July 22, 2008, at F5; see EWG’s Sunscreen Hall of Shame, supra note 128 
(estimating that the bodies of 97% of Americans today are contaminated with 
oxybenzone, which penetrates human skin). 
 130. CDC: Americans Carry Body Burden of Toxic Sunscreen Chemical, ENVTL. 
WORKING GRP. (Mar. 25, 2008), http://www.ewg.org/news/testimony-official-
correspondence/cdc-americans-carry-body-burden-toxic-sunscreen-chemical. 
 131. Parabens, BREAST CANCER FUND, http://www.breastcancerfund.org/clear-
science/chemicals-glossary/parabens.html (last visited Feb. 20, 2014). 
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shampoos to creams.132  In discussing parabens in cosmetics, the 
FDA states that “[t]he [FDCA] does not authorize FDA to approve 
cosmetic ingredients,”133 but comments that a study in 2004 
found parabens in breast tumors.134  The FDA goes on to note 
that these chemicals have also been found at unusual levels in 
the breast tissue of women diagnosed with breast cancer,135 and 
additionally, that parabens “can act similarly to estrogen.”136 
However, the FDA then notes that parabens exhibit much less 
intense estrogenic activity than natural estrogens, and that at 
this time, consumers should not be concerned about parabens in 
cosmetic products.137  The FDA goes further with this line of 
rhetoric, and promises that it has continued to “evaluate new 
data in this area” and that it will consider its “legal options” 
under the FDCA to protect the health and welfare of 
consumers.138 
What is noteworthy about these statements is that the FDA 
takes this position of inaction even while acknowledging that 
estrogenic activity in the body is associated with breast 
cancers.139  This approach to paraben regulation provides an 
illustration of how hamstrung the FDA is in regulating cosmetic 
ingredients and the overall U.S. regulatory approach—chemicals 
are presumed safe until proven definitively guilty.140 
 
 132. Id. 
 133. Parabens, FDA, http://www.fda.gov/forconsumers/consumerupdates/ 
ucm128042.htm (last visited Feb. 20, 2014) [hereinafter FDA Parabens]. 
 134. Id. 
 135. See id. 
 136. Id. 
 137. FDA Parabens, supra note 133. 
 138. Id. 
 139. Id.  In discussing paraben research, the FDA cites a study published in 
2004 (Darbre, in the Journal of Applied Toxicology) that detected parabens in 
breast tumors, noting the weak estrogen-like properties of parabens, and the 
influence of estrogen on breast cancer.  The FDA states, “[h]owever, the study 
left several questions unanswered.  For example, the study did not show that 
parabens cause cancer, or that they are harmful in any way, and the study did 
not look at possible paraben levels in normal tissue.”  Id.  The FDA in these 
comments assumes parabens are safe at low levels in the human body, citing an 
absence of definitive proof that they cause cancer. 
 140. See Tiffany O’Callaghan, President’s Panel Analyzes Environmental 
Cancer Impact, TIME MAG. (May 6, 2010), http://healthland.time.com/2010/05/06/ 
presidents-panel-analyzes-environmental-cancer-impact/. 
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Perhaps one should not be surprised by this approach as we 
have a long history of regulating in this regard.  Cigarettes, for 
example, were used without recourse and without government 
warning until 1966 with the passage of the Federal Cigarette 
Labeling and Advertising Act of that year.141  During the period 
prior to the passage of the 1966 Act, there is much evidence that 
the tobacco industry hid information from the public that 
cigarettes were causative of lung cancer.142  Yet, the government 
did not even begin to require warnings on cigarette packages or 
otherwise warn the public of the dangers of tobacco smoking until 
the 1960s.143  In essence, cigarette and tobacco use were assumed 
safe for many years after they were suspected of grave harm, and 
federal warnings were not mandated until definitive proof could 
be offered linking cigarette smoking and cancer.  
Similarly, the government hesitated to warn that 
formaldehyde, a commonly used chemical in manufacturing, still 
a byproduct in cosmetic formulations,144 and found today in 
particle board and other wood products,145 was a danger.146  In 
1982, it refused to issue a warning and label formaldehyde, a 
likely human carcinogen, stating that it did not have enough 
information to do so.147  It was not until 2011 that the National 
 
 141. Federal Cigarette Labeling and Advertising Act, Pub. L. No. 89-92, 79 
Stat. 282 (1965) (codified at 15 U.S.C. §§ 1331-1341).  The Cigarette Labeling 
and Advertising Act became effective on January 1, 1966.  Id. § 11. 
 142. See, e.g., Ingrid L. Dietsch Field, No Ifs, Ands or Butts: Big Tobacco is 
Fighting for Its Life Against a New Breed of Plaintiffs Armed with Mounting 
Evidence, 27 U. BALT. L. REV. 99, 120-22 (1997) (discussing evidence from 
whistleblowers and others revealing that tobacco companies knew for decades of 
the addictive and dangerous nature of smoking, and hid such dangers from the 
public). 
 143. Pub. L. No. 89-92, 79 Stat. 282, 282 (1965); Matthew Baldini, The 
Cigarette Battle: Anti-Smoking Proponents Go For the Knockout, 26 SETON HALL 
L. REV. 348, 348 (1995) (noting that the federal government first addressed 
publicly and noted the health impact of smoking in the Surgeon General’s 
Advisory Committee report in 1964). 
 144. See supra notes 3-5 and accompanying text. 
 145. NAT’L TOXICOLOGY PROGRAM, U.S. DEP’T OF HEALTH & HUMAN SERVS., 
REPORT ON CARCINOGENS: FORMALDEHYDE, 195, 200 (12th ed. 2011), available at 
http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/formaldehyde.pdf. 
 146. Id. at 201 (noting, based on an analysis of the FDA’s voluntary cosmetic 
product information database, almost 20% of cosmetics contain formaldehyde or 
certain formaldehyde-releasing preservatives). 
 147. See 47 Fed. Reg. 14366 (Apr. 2, 1982) (notice of final rule banning certain 
uses of formaldehyde products, in which the Consumer Product Safety 
23
  
618 PACE ENVIRONMENTAL LAW REVIEW [Vol.  31 
Institutes of Health officially determined that formaldehyde is a 
known human carcinogen.148 
These are just a few instances where the U.S. government 
failed to regulate a potentially toxic substance in a precautionary 
manner to protect human health—instances in which the 
government sided with industry even in the face of mounting 
evidence of harm. 
Yet, EDCs in our current regulatory system present a 
particularly troublesome quagmire for a number of reasons.  
First, it is uniquely difficult to determine which of the more than 
80,000 chemicals on the market,149 and at what exposure level, 
have the potential to disrupt the human endocrine system.150  
Second, these types of chemicals have the potential for 
incalculable risk.151  EDCs threaten the ability of wildlife to 
reproduce,152 and scientists believe they may be affecting humans 
in this same vein.153 
To complicate matters, as to the vast cornucopia of additional 
existing chemicals and their degradation products, scientists have 
not even identified all those that are EDCs.154  The EPA has 
estimated that approximately 87,000 synthetic (man-made) 
 
Commission stated that current evidence was insufficient to conclude that 
formaldehyde was carcinogenic to humans). 
 148. NAT’L TOXICOLOGY PROGRAM, supra note 145, at 195 (formaldehyde was 
listed as “reasonably anticipated to be a human carcinogen” in 1981, and its 
status was changed to “known to be a human carcinogen” in 2011). 
 149. See Letter to the President, supra note 106.  See generally H.R. 1385, 
113th Cong. (2013); 2013 News Coverage, CAMPAIGN FOR SAFE COSMETICS, http:// 
safecosmetics.org/section.php?id=86 (last visited Feb. 21, 2014). 
 150. See REPORT NO. 11-P-0215, supra note 95, at iii (noting that fourteen 
years after the passage of the FQPA and the Safe Drinking Water Act, the 
EDSP had not determined yet whether any chemical is an endocrine disruptor); 
Watnick, supra note 68, at 1314-15. 
 151. See REPORT NO. 11-P-0215, supra note 95, at iii. 
 152. See generally COLBORN ET AL., supra note 73. 
 153. Don Mayer, The Precautionary Principle and International Efforts to Ban 
DDT, 9 S.C. ENVTL. L.J. 135, 147-48 (2002) (noting that exposure to 
infinitesimal amounts of an EDC can disrupt animals’ reproductive systems); 
Raphael J. Witorsch, Endocrine Disruption—History, Fact, and Fantasy of 
Gender Bending Chemicals, 6 FOOD & DRUG L. INST. 32, 32 (2002) (noting a 50% 
decrease in sperm production worldwide between 1940 and 1990); Fassuliotis, 
supra note 84, at 357-60. 
 154. See Mayer, supra note 153, at 147.  Scientists continue to recognize an 
ever-increasing number of chemicals as EDCs.  See NEHA Position on EDCs, 
supra note 119. 
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chemicals need to be screened155 for their potential endocrine 
disrupting effects,156 and still new chemicals are developed and 
marketed every day.157 
In the regulation of cosmetic products, we have taken a 
brazen “non-precautionary” approach—ignoring these potential 
risks and avoiding regulation and required testing.  It is plainly 
untrue that chemicals used in cosmetics are required to be 
thoroughly tested in the United States before they are sold.158  
Rather, we allow industry to market chemicals to adults and 
children before they are extensively tested, and then wait to see if 
human health effects occur.159  Dr. Richard Clapp, a professor of 
epidemiology at Boston University School of Public Health, and 
one of the experts who submitted testimony contributing to the 
2010 President’s Cancer Panel’s report, has said that with regard 
to the current policy, “you have to wait until the bodies are 
counted before you can go back and say, ‘Oh, you shouldn’t allow 
people to be exposed to that chemical.’”160 
 
 155. Endocrine Disruptor Screening Program (EDSP): Endocrine Primer, EPA, 
http://www.epa.gov/endo/pubs/edspoverview/primer.htm (last visited Feb. 21, 
2014) (noting that the EPA has insufficient data to assess the estimated 87,000 
chemicals produced today for endocrine associated effects). 
 156. Mayer, supra note 153, at 147-48. 
 157. See COLBORN ET AL., supra note 73, at 106 (“Virtually anyone willing to 
put up the $2,000 for the tests will find at least 250 chemical contaminants in 
his or her body fat, regardless of whether he or she lives in Gary, Indiana, or on 
a remote island in the South Pacific.”); O’Brien, supra note 40, at 337 (noting 
that “worldwide, 100,000 synthetic chemicals are on the market,” and that 
chemical contamination and pollution is ubiquitous).  One of the reasons that 
synthetic chemicals are ever-present is that they often persist in the 
environment and accumulate in the fatty tissue of animals.  See id.  Every year, 
1,000 new synthetic chemicals are put on the market, most without testing for 
toxic effects.  Id.; see also Applegate & Campbell-Mohn, supra note 78, at 221 
(purporting that variables used to calculate exposure and risk of toxics are 
based on scientists’ and policymakers’ judgments and assumptions, rather than 
on certainty). 
 158. See infra notes 159-62 and accompanying text.  See generally CARL F. 
CRANOR, LEGALLY POISONED: HOW THE LAW PUTS US AT RISK FROM TOXICANTS 
(2011) (offering a thorough discussion of the problem with testing and lack of 
cosmetics regulation).   
 159. Walmart Will No Longer Sell Cosmetics, Cleaners, Made with Targeted 
List of Toxic Chemicals, CAMPAIGN FOR SAFE COSMETICS, http://safecosmetics.org/ 
article.php?id=1157 (last visited Feb. 21, 2014) (noting that Walmart has 
decided to ban cosmetics with ten particularly toxic substances). 
 160. O’Callaghan, supra note 140. 
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In a letter to President Obama that prefaced the President’s 
Cancer Panel’s report, the authors point out that the nearly 
80,000 chemicals on the market in the United States that are 
used by millions of Americans everyday are largely untested, and 
that exposure to potential environmental toxins is widespread.161  
The report noted that “[o]ne such ubiquitous chemical, bisphenol 
A (BPA), [a suspected EDC and carcinogen], is still found in many 
consumer products and remains unregulated in the United 
States, despite the growing link between BPA and several 
diseases, including various cancers.”162 
C.  EDCs Are Difficult to Assess 
Overall, the science of EDCs163 and their effect on humans is 
still relatively new and in need of greater study.  But the fact that 
harm from them may also be dependent on an inverse bell 
curve,164 meaning that lower level exposures may turn out to be 
more harmful than higher exposures, suggests that these 
chemicals present a particularly troubling regulatory scenario,165 
especially when found in varying degrees in cosmetic products.  
These chemicals simply do not lend themselves to traditional 
QRA.166  Even given all of its shortcomings as an assessment tool, 
QRA, by its regulatory existence, at least forces regulators (and 
the public) to acknowledge, and, at the minimum, consider the 
potential harm of a substance.167 
With regard to EDCs, however, we are simply not 
scientifically equipped to make well-educated long-term estimates 
of risk from exposure to these chemicals, and this inability vexes 
 
 161. See Letter to the President, supra note 106. 
 162. Id. 
 163. The National Research Council calls EDCs “hormonally active agents,” 
and the National Academies Press has published a book by this name.  See 
generally NAT’L RESEARCH COUNCIL, HORMONALLY ACTIVE AGENTS IN THE 
ENVIRONMENT (1999).  A new study, funded in part by the National Institute of 
Environmental Health Sciences, also notes that exposure to BPA during 
pregnancy may affect thyroid hormone levels in pregnant women and newborn 
boys.  See Chevrier et al., supra note 78, at 3. 
 164. See Endocrine Disruptors, supra note 78 (noting that small amounts of 
EDCs may be problematic). 
 165. See Watnick, supra note 68, at 1322-23. 
 166. See Watnick, supra note 97, at 1334-35. 
 167. See Watnick, supra note 68, at 1317. 
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our ability to begin to regulate them effectively.168  One 
additional factor that complicates the current regulation of EDCs 
is that it is not feasible to determine safe exposure levels in the 
complex and interrelated world in which we live—a world in 
which different individuals respond differently to different 
chemical exposures and differing amounts of these exposures.169  
Every day, people are exposed to multiple chemicals, some of 
them suspected of endocrine disruption.170  The chemicals in our 
environments may have different effects on different people,171 
and the various chemicals encountered may have synergistic or 
cumulative effects depending on an individual’s past exposures 
and the cumulative body burden.172  The majority of our collective 
research has been done in isolation—testing one chemical at a 
time for its effects on living tissue—when in reality, chemicals 
often act in concert.173  In real life, we are bombarded on a daily 
basis with multiple chemicals in the environment,174 in our 
water, and in our food.  While one or more of these may exhibit 
endocrine disrupting properties alone, the effects when combined 
with other exposures may be synergistic and/or cumulative.175  
And finally, in this complicated scenario, even if we could 
determine safe exposure levels to various EDCs,176 we would then 
 
 168. See id. at 1321-23. 
 169. See supra notes 72-88, 163-64 and accompanying text. 
 170. See Watnick, supra note 97, at 1349 n. 251. 
 171. Id. at 1319 nn. 28-29 (noting that in performing risk assessment, 
scientists consider the different effects that a substance may have on varying 
individuals, often called intraspecies variation, as well as interspecies 
variation). 
 172. See O’ Brien, supra note 40, at 348-54.  Many suspected EDCs are also 
persistent organic pollutants, which are not water-soluble, are stored in fat cells, 
and are difficult for the human body to excrete after exposure.  See RACHEL 
CARSON, SILENT SPRING, 21-27, 178-80, 189-91 (1962). 
 173. O’Brien, supra note 40, at 350-51. 
 174. Toxic Substances in Our Environment, OR. HEALTH AUTH., http://public. 
health.oregon.gov/HealthyEnvironments/EnvironmentalExposures/ToxicSubsta
nces/Pages/index.aspx (last visited Feb. 21, 2014); see O’Brien, supra note 40, at 
348-51. 
 175. Mary L. Lyndon, The Toxicity of Low-Dose Chemical Exposures: A Status 
Report and a Proposal, 52 JURIMETRICS 457, 475 (2012) (reviewing CARL F. 
CRANOR, LEGALLY POISONED: HOW THE LAW PUTS US AT RISK FROM TOXICANTS 
(2011)). 
 176. See supra notes 149-57, 163-75 and accompanying text. 
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have the enormously difficult task of ensuring compliance with 
these pre-determined “safe” exposure levels. 
III.  “GAPING HOLES” IN U.S. COSMETICS 
LEGISLATION AND PROPOSALS FOR CHANGE 
A.  The Current FDA Regulations on Cosmetic Products 
Are Too Lax and Contain “Gaping Holes” 
a.  Pre-approval of Cosmetic Ingredients is Lacking 
The FDA does not pre-approve cosmetic products or 
ingredients before distribution.177  Although FDA regulations 
state that “[e]ach ingredient used in a cosmetic product and each 
finished cosmetic product shall be adequately substantiated for 
safety prior to marketing,” the inclusion of a warning simply 
noting that “[t]he safety of this product has not been determined” 
is sufficient to allow a manufacturer to legally distribute the 
product.178  There is, therefore, no prospective determination, as 
there is under the new European Union regulations179 that a 
product formulation or ingredient is safe.  Rather, in the absence 
of data, all cosmetic products and formulations are presumed safe 
until definitely proven otherwise.  With limited exceptions, 
manufacturers can use any ingredient in their product as long as 
the ingredient and the cosmetic product are safe (or the lack of a 
safety determination is noted), the product is properly labeled, 
and does not otherwise constitute an “adulterated” or 
“mislabeled” product under the FDCA.180  Additional regulations 
set up voluntary programs for the registration of cosmetic product 
manufacturers181 and of cosmetic ingredient statements.182 
 
 177. Cosmetics: FDA Authority over Cosmetics, FDA, (Aug. 3, 2013), http:// 
www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/ucm074162
.htm. 
 178. 21 C.F.R. § 740.10(a). 
 179. See infra notes 216, 226-30 and accompanying text. 
 180. Id. 
 181. See 21 C.F.R. §§ 710.1-710.9. 
 182. See id. §§ 720.1-720.9. 
28http://digitalcommons.pace.edu/pelr/vol31/iss3/1
  
2014] U.S. REGULATION OF COSMETIC PRODUCTS 623 
Although a series of FDA regulations do prohibit or restrict 
the use of certain limited ingredients in cosmetic products,183 the 
regulations overall rely too heavily on voluntary industry efforts 
and contain huge loopholes.184  For example, existing regulations 
provide a process for manufacturers to request that certain 
cosmetic ingredients be kept confidential as proprietary data,185 
data that the makers then do not need to list on a cosmetic 
ingredient list.186  Manufacturers thus do not have to disclose all 
of the ingredients in their products if they bury certain 
ingredients in proprietary information, using ingredient code 
words such as “fragrance” or “flavor.”187  These one-word phrases 
are often allowed in place of the actual list of ingredients that 
make up the fragrance or flavor.188 
Moreover, there is absolutely no incentive for a manufacturer 
to test its product ingredients for ill health effects, including 
endocrine, carcinogenic, reproductive, or neurotoxic effects, even 
though the manufacturer is in the best position to do so.189  Such 
 
 183. See id. §§ 700.11, 700.13, 700.14, 700.15, 700.16, 700.18, 700.19, 700.23, 
700.27 (regulating bithionol, mercury, vinyl chloride, halogenated 
salicylanilides, zirconium, chloroform, methylene chloride, chlorofluorocarbons, 
and certain cattle materials at heightened risk of infection with bovine 
spongiform encephalopathy, respectively). 
 184. See supra notes 37-40, 64-69 and accompanying text; see infra notes 327, 
331-37 and accompanying text. 
 185. The listed factors to determine whether an ingredient qualifies as a 
confidential trade secret are: 
(1) The extent to which the identity of the ingredient is known 
outside petitioner's business; (2) [t]he extent to which the identity of 
the ingredient is known by employees and others involved in 
petitioner's business; (3) [t]he extent of measures taken by the 
petitioner to guard the secrecy of the information; (4) [t]he value of 
the information about the identity of the claimed trade secret 
ingredient to the petitioner and to its competitors; (5) [t]he amount 
of effort or money expended by petitioner in developing the 
ingredient; and (6) [t]he ease or difficulty with which the identity of 
the ingredient could be properly acquired or duplicated by others. 
21 C.F.R. § 720.8(b). 
 186. Id. § 701.3(a). 
 187. Id. 
 188. See id. 
 189. See, e.g., Pine St. Trading Corp. v. Farrell Lines, Inc., 364 A.2d 1103, 
1109 (Md. 1976) (noting that the government has the burden to prove a product 
is dangerous in an condemnation action); United States v. Wash. Dehydrated 
Food Co., 89 F.2d 606, 608 (8th Cir. 1937) (noting that the government’s burden 
of proof is the same as under the former Pure Food and Drug Act). 
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testing, if conducted at the manufacturer’s expense, might lead 
the FDA to determine that a product is adulterated or 
misbranded, and to therefore prohibit the sale and distribution of 
the product.190  A cosmetics manufacturer is better served in 
terms of marketing its product most efficiently—although 
perhaps not most ethically—to simply state that a product lacks 
appropriate safety data or proof of efficacy prior to manufacturing 
and sale.191  To begin to protect human health, Congress must 
pass legislation requiring pre-market safety testing of cosmetics 
ingredients and products.192 
b.  The FDA Must Have Recall Power Based on the 
Reasonable Belief that a Substance is Harmful 
The FDA currently does not have authority to require a 
mandatory recall of cosmetics.193  This lack of recall power, and 
the manner in which it severely hampers FDA regulatory efforts, 
has been the cause of much consternation among consumers, 
activists, and congressional staff seeking more rigorous 
regulation of cosmetics.194  The FDA has no general power of 
recall—it may only require recall where a court action is 
instituted and upheld against a mislabeled or adulterated 
product, thereby allowing the seizure of such product.195 
 
 190. See Wendy E. Wagner, Choosing Ignorance in the Manufacture of Toxic 
Products, 82 CORNELL L. REV. 773, 775 (1997) (noting that “[a] manufacturer 
that conducts no research can generally avoid liability because plaintiffs and 
government research programs are unlikely to conduct scientific research on 
their own”). 
 191. See Wagner, supra note 190, at 775. 
 192. See supra notes 37-40, 64-69 and accompanying text. 
 193. Id. 
 194. See, e.g., Victoria Farren, Note, Removing the Wrinkle in Cosmetics and 
Drug Regulation: A Notice Rating System and Education Proposal for Anti-
Aging Cosmeceuticals, 16 ELDER L.J. 375, 393 (2009). 
 195. 21 C.F.R. § 7.40(a), (c) (2014) (“(a) Recall . . . [of] consumer products that 
are in violation of laws administered by the [FDA] . . . is a voluntary action. . . .  
(c) [S]eizure . . . or other court action is indicated when a firm refuses to 
undertake a recall requested by the [FDA] . . . .”).  Only through court action can 
the FDA mandatorily seize and stop the distribution of unsafe cosmetics.  See 21 
U.S.C. § 334(a); see also United States v. Eight Unlabeled Cases, 888 F.2d 945, 
946, 949 (2d Cir. 1989) (affirming the FDA’s forfeiture and condemnation action 
regarding an adulterated cosmetic product). 
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c.  Cosmetics Regulation Must Account for the Long-
Term Effects of Exposure 
Perhaps the most worrisome failure of our toxics regulatory 
system in general, and with regard to cosmetics in particular, is 
that it makes no meaningful accounting for the long-term effects 
of consumer products on human health.196  EDCs in particular 
have been shown to have long-lasting, intergenerational 
effects,197 as well as associations with cancer in future 
generations many decades after exposure.198 
d.  Cosmetics Regulation Must Account for the 
Differences Between Adults and Children 
Our regulation of cosmetics also does not address concerns 
specific to children.  The news over toxic chemicals in baby 
shampoo highlights the fact that cosmetic products designed for 
children are not subject to rigorous regulation.199  Children are 
particularly susceptible to toxins in cosmetic products, as they 
take in more air and water per pound of body weight,200 and have 
longer future lives to carry the burden of persistent chemicals in 
their bodies.201  Additionally, they have immature skin that may 
be more receptive to the absorption of toxins.202  Revised health 
protective cosmetics regulations would take the differences 
between adults and children into account, and would provide for 
more health protective regulation in products designed for use on 
children and babies. 
e.  Consumers Have a False Sense of Security 
Finally, the biggest mistake in our cosmetic regulation 
paradigm may be that it gives consumers a false sense of security.  
Many consumers likely believe that the FDA exerts strong and 
 
 196. See supra notes 37-40 and accompanying text. 
 197. See supra notes 70-88 and accompanying text. 
 198. See supra notes 83-88 and accompanying text. 
 199. See supra notes 1-9 and accompanying text. 
 200. See supra notes 109-116 and accompanying text. 
 201. CRANOR, supra note 158, at 102-03. 
 202. Id. at 103. 
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powerful authority over cosmetic manufacturers.203  Consumers 
would likely be shocked to learn that the FDA barely has the 
power to recall a cosmetic product suspected of potential harm.  
Yet, consumers see federal regulation in place, and they may 
assume that all that is in their drugstore is safe.  The very 
existence of federal regulation, coupled with perceived FDA 
oversight, and the FDA’s actual lack of strong regulatory 
authority likely gives consumers an unwarranted and false sense 
of security that lulls the populace into complacency. 
f.  Nanoparticles Are Not Regulated 
Other than the recent and somewhat limited amendment to 
the FDCA, that merely encourages the FDA to further scientific 
study of nanomaterials,204 there are no provisions under current 
U.S. law or regulation that begin to fully address health concerns 
over nanotechnology in consumer products.  As noted above, 
manufacturers have no financial incentive to study 
nanotechnology, but can continue to market and sell these 
formulations in the absence of information that they are harmful 
to human health.205  The use of such particles should be 
disallowed pending safety studies, but at the very least, federal 
regulations must require labeling of products containing 
nanoparticles so that consumers can make informed decisions 
about whether to choose such products. 
B.  The Normative Goal Must Shift in How We Regulate 
Consumer Products to Protect Human Health and the 
Environment 
The idea that “[w]e can and should develop and apply 
standards that ensure safety to human health in our toxics 
 
 203. As far back as the 1960s, the public seemed to believe that the 
government was protecting “us.”  See CARSON, supra note 172, at 181 (“To the 
question, ‘But doesn’t the government protect us from [pesticide 
contamination]?’ the answer is, ‘Only to a limited extent.’”) (noting that in that 
time period, the activities of the FDA were severely hampered by a lack of 
resources, and that state laws were not protective). 
 204. See supra notes 49-55 and accompanying text. 
 205. See id. 
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regulatory schemes,”206 including as they relate to cosmetics and 
other consumer products, does not have solid basis in the political 
and scientific reality of the current world.207  Rather, our efforts 
are directed at regulating to achieve a level of risk that is 
“politically acceptable.”208  Indeed, since consumers seem 
unaware of the FDA’s lack of authority and real oversight in the 
cosmetics arena, and even assume stringent federal regulation,209 
it seems obvious from a political point of view, for politicians to 
continue to endorse this loose cosmetics regulatory system.  In 
place of strong federal oversight, the cosmetics industry is instead 
largely allowed to self-police and market most products as they 
see fit, absent some showing by the public of clear potential for 
human harm.210 
Even if safety were the true goal of toxics regulation and the 
regulation of cosmetic products, the creation of safety-based 
standards to regulate toxins is not a practical goal.211  There exist 
 
 206. Watnick, supra note 68, at 1305.  Both the Clean Air Act and the Safe 
Drinking Water Act require the measurement of risk through the process of risk 
assessment and risk management.  See Applegate & Campbell-Mohn, supra 
note 78, at 222 (noting that risk assessment has come to dominate Congress’ 
approach to toxics regulation). 
 207. Watnick, supra note 68, at 1305-06. 
 208. It is fair to note that the change in emphasis in toxics regulation from 
safety to acceptable risk occurred fairly recently in the 1980s as the regulatory 
system became solidly based on risk assessment.  See supra notes 98-102 and 
accompanying text.  The author would assert however, that the public is 
unaware of this dramatic shift in regulatory emphasis.  Indeed, I have argued in 
the past that politicians and regulators achieve regulatory obfuscation by using 
terminology and standards that imply safety, using QRA where mandated, and 
stating that risk levels are negligible: 
For example, the FQPA states that all tolerances must be “safe.”  21 
U.S.C. § 346a.  However, “safe” means that there exists a 
“reasonable certainty that no harm will result from aggregate 
exposure” to the pesticide residues from food and other exposures, id. 
§ 346a(b)(2)(A)(ii), and this is generally assumed to mean that there 
exists a one-in-one-million chance that an effect will occur. Cf. Jay 
Michaelson, Rethinking Regulatory Reform: Toxics, Politics and 
Ethics, 105 YALE L.J. 1891, 1899 (1996).  [. . .]  This negligible risk 
standard is designed in keeping with the assumption that our food 
supply is not ever one hundred percent safe.  See id.  The one-in-one-
million standard might be deemed politically acceptable risk. 
Watnick, supra note 68, at 1306 n. 8. 
 209. See Wagner, supra note 190, at 774. 
 210. See supra notes 56-69 and accompanying text. 
 211. See Watnick, supra note 68, at 1307. 
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over 80,000 chemicals on the market today, the vast majority of 
which have not been tested for endocrine or other toxic effects.212 
If we are to regulate these chemicals from a more health 
protective stance, our thinking on how we regulate synthetic 
substances—and especially those marketed for everyday 
consumer use—must change.  Toward such ends, the 
precautionary principle mandates that when a substance is 
suspected of harm to human health, the substance is heavily 
regulated and restricted, until evidence is available to indicate 
that the product is not a danger to human health.213  Under a 
new norm in line with the precautionary principle, products and 
synthetic chemicals would not be given the benefit of the doubt—
they would not be “presumed innocent until proven guilty,” as 
under the current system.  This type of approach would be more 
consistent with those adopted in Europe and Canada, and more 
health protective.  
IV.  FOREIGN AND STATE-LEVEL COSMETICS 
REGULATION 
A.  European Cosmetics Regulation 
The European Union (EU)214 began regulating cosmetics in 
1976 through the Cosmetics Directive.215  Overall, the Cosmetics 
Directive is far more protective of human health than U.S. 
regulation.  While the EU’s labeling requirements are largely in 
line with U.S. requirements,216 new EU regulations now go so far 
as to require some prospective safety findings, and also prohibit 
certain ingredients in cosmetics. 
The original EU Cosmetics Directive requires that cosmetic 
products “must not cause damage to human health when applied 
 
 212. See Letter to the President, supra note 106. 
 213. See John S. Applegate, The Taming of the Precautionary Principle, 27 
WM. & MARY ENVTL. L. & POL’Y REV. 13, 13 (2002). 
 214. Frequently Asked Questions (FAQ), COUNCIL OF THE EUROPEAN UNION, 
http://www.consilium.europa.eu/contacts/faq?lang=en&faqid=79264 (last visited 
Feb. 21, 2014) (noting that the EU was known as the European Community 
until 1993). 
 215. See generally Council Directive 76/768, 1976 O.J. (L 262) 12 (EC) 
[hereinafter EU Cosmetics Directive]. 
 216. Id. art. 6. 
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under normal or reasonably foreseeable conditions of use, taking 
account . . . the product’s presentation, its labeling, any 
instructions for its use and disposal as well as any other 
indication or information provided by the manufacturer . . . .”217  
The Cosmetics Directive further states that the inclusion of a 
warning label does not exempt a manufacturer or product from 
any requirements under the Cosmetics Directive.218  The 
Cosmetics Directive includes listings of prohibited ingredients, 
restricted ingredients, as well as permitted colorants, 
preservatives, and ultraviolet filters.219  Prohibited ingredients 
include those that are “carcinogenic, mutagenic or toxic for 
reproduction” pursuant to the EU’s Dangerous Substances 
Directive.220  The Cosmetics Directive also requires cosmetics 
manufacturers to make the following information available for 
government regulators: (1) the composition of the product; (2) the 
“physico-chemical and microbiological specifications” of all 
ingredients and the final product; (3) the method of manufacture 
of the product; (4) information regarding the assessment of the 
product’s safety for human health; (5) data on adverse health 
effects from the use of the product; (6) proof of the product’s 
effectiveness; and (7) information on any animal testing relating 
to the product.221  A country in the EU may ban or restrict the 
 
 217. Id. art. 2. 
 218. Compare EU Cosmetics Directive, supra note 215 with 21 C.F.R. § 
740.10(a) (providing that a warning label allows the distribution of a product 
even if it has not yet been substantiated as safe). 
 219. EU Cosmetics Directive, supra note 215, art. 4; JAN VERNON & TOBE A. 
NWAOGU, RISK & POL’Y ANALYSTS LTD., COMPARATIVE STUDY ON COSMETICS 
LEGISLATION IN THE EU AND OTHER PRINCIPAL MARKETS WITH SPECIAL ATTENTION 
TO SO-CALLED BORDERLINE PRODUCTS 20 (2004), available at http://www.pedz. 
uni-mannheim.de/daten/edz-h/gdb/04/j457_-_final_report_-_cosmetics.pdf 
(noting over 400 items on the prohibited list). 
 220. EU Cosmetics Directive, supra note 215, art. 4b. 
 221. Id. art. 7a (noting that with respect to information relating to the 
product’s safety, the manufacturer “shall take into consideration the general 
toxicological profile of the ingredients, their chemical structure and their level of 
exposure,” taking particular account of “the specific exposure characteristics of 
the areas on which the product will be applied or of the population for which it is 
intended”). 
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distribution of a product upon receiving information that such 
product represents a health hazard.222 
In 2009, the European Parliament and Council further 
strengthened the health protectiveness of the Cosmetics 
Directive.223  The new regulation, effective July 11, 2013, with 
some provisions in effect earlier,224 called the New Cosmetics 
Regulation, provides that manufacturers—or importers, as 
applicable—must take immediate corrective measures to rectify 
non-conformity with the regulation, including withdrawing or 
recalling affected products, and immediately informing national 
regulators when a product presents a health risk.225 
The real meat of the New Cosmetics Regulation is that prior 
to marketing a cosmetic product, a manufacturer must assess the 
safety of the product, and establish a cosmetic product safety 
report.226  Information must be provided to the European 
Commission, including the presence of any nanomaterials—and 
their expected exposure conditions—and substances classified as 
“carcinogenic, mutagenic, or toxic for reproduction.”227  Under the 
New Cosmetics Regulation, manufacturers—or importers—shall 
maintain a product information file containing safety information 
on each product for a period of ten years following the date that 
 
 222. Id. art. 12.  The Cosmetics Directive also contains a ban on products that 
involved testing on animals, id. art 4a, and requires that an inventory of 
ingredients used in cosmetics be compiled and published.  Id. art. 5a. 
 223. See generally Regulation 1223/2009, of the European Parliament and of 
the Council of 30 Nov. 2009 on cosmetic products, 2009 O.J. (L 352) 59 
[hereinafter EU Cosmetics Regulation]. 
 224. EU Cosmetics Regulation, supra note 223, art. 40. 
 225. Id. art. 5.2.  Distributors face obligations similar to importers and 
manufacturers of cosmetics.  Id. art. 6.  Manufacturers must always comply with 
good manufacturing practices.  Id. art. 8.  Compliance is presumed when 
processes comply with harmonized standards, as referenced in the EU’s official 
journal.  Id. art. 8.2. 
 226. See id. art. 10.1, 13.1. 
 227. Id. art. 13.1(f), (g).  The New Cosmetics Regulation defines 
“nanomaterial” as “an insoluble or biopersistant and intentionally manufactured 
material with one or more external dimensions, or an internal structure, on the 
scale from 1 to 100 nm.”  Id. art. 2.1(k).  The definition of “nanomaterials” will 
be adjusted in accordance with technical and scientific developments in the 
nanotechnology field.  Id. art. 2.3. 
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the last batch of product was placed on the market, and shall 
make this information available to national regulators.228 
This requirement of prospective safety information markedly 
contrasts with current U.S. regulations, pursuant to which a 
product is presumed safe unless information exists to suggest 
otherwise.  Additionally, the New Cosmetics Regulation calls for 
identification of EDCs in cosmetic products on an expedited basis.  
While the New Cosmetics Regulation continues the categorization 
of materials with permitted, restricted, and prohibited 
designations,229 it provides for the amendment of an existing 
categorization when substances are identified as EDCs.230 
The New Cosmetics Regulation also takes a proactive 
approach concerning nanomaterials in cosmetics.231  It states that 
“[f]or every cosmetic product that contains nanomaterials, a high 
level of protection of human health shall be ensured.”232  The 
regulation requires manufacturers to identify: (1) the “size of 
particles, physical and chemical properties” of the nanomaterials; 
(2) an estimated amount of nanomaterials in cosmetics to be 
marketed per year; (3) the toxicological profile of the 
nanomaterial; (4) safety data of the nanomaterial; and (5) 
“reasonably foreseeable exposure conditions.”233  Where there is a 
potential risk to human health regarding nanomaterials, 
including when there is insufficient data available, the European 
Commission may add such materials to the restricted or 
prohibited ingredient lists.234  Additionally, the regulation calls 
for the European Commission to make available to the public, by 
January 11, 2014, a list of all nanomaterials used in cosmetic 
products placed on the market.235 
 
 228. Id. art. 11  (requiring the product information file to contain information 
similar to that required under the Article 7a of the Cosmetics Directive).  See 
EU Cosmetics Directive, supra note 215, art. 7a. 
 229. EU Cosmetics Regulation, supra note 223, art. 14.1(a)-(b).  The New 
Cosmetics Regulation also continues the ban on animal testing, and contains 
similar product labeling requirements as in the Cosmetics Directive.  Id. art. 
18.1, 19.1. 
 230. Id. art. 15.4. 
 231. Id. art. 16.1. 
 232. Id. 
 233. Id. art. 16.3. 
 234. Id. art. 16.6. 
 235. EU Cosmetics Regulation, supra note 223, art. 16.10(a). 
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Moreover the manufacturer, importer and/or distributor are 
also required to report “serious undesirable effects” to the 
relevant national regulator.236  When there is serious doubt 
concerning the safety of a substance contained in cosmetics, 
national regulators may request from manufacturers or importers 
a list of all their products containing such substance.237 
Regulators may likewise require the manufacturer to 
withdraw or recall products for failure to comply with the New 
Cosmetics Regulation.238  Such withdrawal or recall may be 
enforced if necessary to prevent serious health risk or if the 
manufacturer does not do so voluntarily.239 
Overall, while not entirely of the long-term view, the EU’s 
cosmetic regulations take a prospective and cautionary stance 
toward protecting human health.240  In calling for disclosure of 
ingredient usage, such as the usage of nanomaterials241 or 
suspected endocrine disrupting chemicals242 in cosmetics, 
requiring prospective safety information, and providing the 
government with the ability to recall and force the withdrawal of 
products where there is doubt concerning the safety of a 
product,243 the EU’s New Cosmetics Regulation is decidedly more 
health protective than existing U.S. regulations.  In all of the 
aforementioned ways, the New Cosmetics Regulation contrasts 
 
 236. Id. art. 23.1.  “Undesirable effect” is defined as “an adverse reaction for 
human health attributable to the normal or reasonably foreseeable use of a 
cosmetic product,” while “serious undesirable effect” is “an undesirable effect 
which results in temporary or permanent functional incapacity, disability, 
hospitalization, congenital anomalies or an immediate vital risk or death.”  Id. 
art. 2.1(o)-(p). 
 237. Id. art. 24. 
 238. EU Cosmetics Regulation, supra note 223, art. 25.1. 
 239. Id. art. 25.5(a)-(b). 
 240. See id. art. 23.  New Zealand cosmetic regulations are loosely based on 
the EU regulations, calling for the classification of product ingredients.  See 
Cosmetic Products Regulations Updated, ENVTL. PROT. AUTH., (June 29, 2012), 
http://www.epa.govt.nz/news/erma-media-releases/Pages/Cosmetic-Products-
regulations-updated.aspx (N.Z.).  See generally HAZARDOUS SUBSTANCES AND 
NEW ORGANISMS ACT 1996, ENVTL. PROT. AUTH. (2012) (N.Z.), available at 
http://www.epa.govt.nz/Publications/Cosmetic%20Products%20Group%20Standa
rd.pdf. 
 241. EU Cosmetics Regulation, supra note 223, art. 16.10(a). 
 242. Id. art. 15.4. 
 243. See id. art. 25.1. 
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markedly with the lack of such provisions and FDA authority in 
the United States.244 
B.  Canadian Cosmetics Regulation 
Under the Canadian Food and Drugs Act,245 prohibited 
cosmetics are those: (1) containing “any substance that may cause 
injury to the health of the user . . . [or] any filthy or decomposed 
substance,” or (2) which were “manufactured, prepared, 
preserved, packaged or stored under unsanitary conditions.”246  
While these regulations at first glance seem similar to U.S. 
cosmetics regulation, the Canadian regulations actually take a 
more health protective stance.  Canadian regulations247 prohibit 
the sale of cosmetics containing an estrogenic substance.248  
Health Canada, the Canadian federal regulator with authority 
over cosmetics, also prepares and updates a Cosmetics Ingredient 
Hotlist, which notes ingredients that are either prohibited or 
restricted from use in cosmetic products.249 
Importantly, the Canadian regulations allow the government 
to request that a manufacturer submit evidence of a cosmetic 
product’s safety, and to require the halting of sales if such 
information is not provided or is incomplete.250  The Canadian 
regulations also require manufacturers and importers to 
promptly file with the government information about the 
manufacture and composition of a cosmetic product within ten 
days of first selling the product.251  As expected, the Canadian 
cosmetic regulations contain general labeling requirements, but 
additionally, the Canadian regulations also prohibit, without 
evidence, labeling claims about: “(a) the ability of the cosmetic or 
any of its ingredients to influence the chemistry of the skin, hair 
or teeth; or (b) the formulation, manufacture or performance of 
 
 244. See supra notes 177-205 and accompanying text. 
 245. See generally Food and Drugs Act, R.S.C. 1985, c. F-27 (Can.). 
 246. Id. § 16. 
 247. See generally Cosmetic Regulations, C.R.C., c. 869 (Can.). 
 248. Id. § 15(b). 
 249. List of Prohibited and Restricted Cosmetic Ingredients (“Hotlist”), HEALTH 
CANADA, http://www.hc-sc.gc.ca/cps-spc/cosmet-person/indust/hot-list-critique/ 
index-eng.php (last visited Feb. 21, 2014). 
 250. C.R.C., c. 869, § 29 (Can.). 
 251. Id. § 30. 
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the cosmetic that would imply that the user . . . will not suffer 
injury to their health.”252 
C.  Regulation of Cosmetics in Japan 
Cosmetic products in Japan are regulated under the 
Pharmaceutical Affairs Law, which was first enacted in 1943.253  
Prior to 2001, manufacturers and importers had to obtain pre-
market approval for every ingredient used in a cosmetic product 
from the Ministry of Health, Labor and Welfare.254  Following a 
deregulation of the cosmetics industry, making the Japanese 
system a mirror of the U.S. system,255 manufacturers and 
importers now merely need to notify the government of the 
product’s brand name prior to distribution.256  The revised 
Japanese cosmetics regulatory system still requires pre-approval 
for the use of certain types of ingredients (e.g. colorants, 
preservatives, and ultraviolet filters),257 and other chemicals not 
subject to pre-approval may be disallowed or only allowed on the 
condition that they are sold with safe use instructions or warning 
labels after government review.258 
D.  State Regulation of Cosmetics—California 
In 1986, Californian voters supported ballot proposal 
Proposition 65, under the Safe Drinking Water and Toxic 
Enforcement Act, to regulate chemicals in drinking water and 
toxic substances in the general environment.259  Although 
Proposition 65 is not directed specifically at cosmetic products, it 
 
 252. Id. § 21.1.  Health Canada can request that such evidence by submitted to 
it by the manufacturer.  Id. § 21.2. 
 253. VERNON & NWAOGU, supra note 219, at 27-28; see Giovanni Pisacane, 
Cosmetics Market Regulation in Asian Countries, 4 HOUSEHOLD & PERSONAL 
CARE TODAY 21 (2009), available at http://www.greatwaylimited.com/admin/ 
upload/Cosmetic%20market%20regulation%20in%20Asian%20Countries.pdf. 
 254. VERNON & NWAOGU, supra note 219, at 29. 
 255. See id. 
 256. Id. 
 257. Janet Winter Blaschke, Globalization of Cosmetic Regulations, 60 FOOD & 
DRUG L.J. 413, 414-15 (2005). 
 258. See id. at 415. 
 259. See Proposition 65, OFFICE OF ENVTL. HEALTH HAZARD ASSESSMENT, 
http://www.oehha.org/prop65. html (last visited Feb. 21, 2014). 
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regulates certain chemicals found in cosmetics.  Proposition 65 is, 
to the author’s knowledge, the most stringent health protective 
toxic substances regulation in the United States. 
Proposition 65 prohibits the discharge of chemicals known to 
cause cancer or reproductive toxicity into the water,260 and 
requires that products containing these chemicals contain a 
warning label.261  Consumer products, including cosmetics, which 
contain materials included on the list of hazardous chemicals in 
Proposition 65, are required to include one of the following 
warnings: “WARNING: This product contains a chemical known 
to the State of California to cause cancer” or “WARNING: This 
product contains a chemical known to the State of California to 
cause birth defects or other reproductive harm.”262 
Proposition 65 also requires California to publish an annual 
list of chemicals that cause cancer or reproductive toxicity.263  
Pursuant to Proposition 65, California thus established the 
Carcinogenic Identification Committee and the Developmental 
and Reproductive Toxicant Identification Committee,264 both to 
determine whether chemicals have been found to cause cancer or 
reproductive toxicity,265 and also to identify federal and 
international bodies whose findings may be considered as 
authoritative.266 
Proposition 65 has thus required stricter, more health 
protective regulation of cosmetics in California.  California’s 
Office of Environmental Health Hazard Assessment, which 
administers the Proposition 65 provisions, for example, lists 
toluene, found often in nail care products, on the annual list of 
hazardous chemicals for which labels are required to warn that 
the chemical  “causes birth defects or other reproductive 
harm.”267   
 
 260. CAL. HEALTH & SAFETY CODE § 25249.5 (West 2014). 
 261. Id. § 25249.6. 
 262. CAL. CODE REGS. tit. 27, § 25603.2 (2014). 
 263. CAL. HEALTH & SAFETY CODE § 25249.8(a). 
 264. CAL. CODE REGS. tit. 27, § 25302. 
 265. Id. § 25305. 
 266. Id. § 25306.  The EPA and the FDA are among the regulatory and other 
bodies that have been identified as authoritative.  Id. § 25306(l)-(m). 
 267. PROPOSITION 65 IN PLAIN LANGUAGE!, OFFICE OF ENVTL. HEALTH HAZARD 
ASSESSMENT 4 (2013), available at http://www.oehha.org/prop65/pdf/P65Plain. 
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In 2005, the California Legislature furthered the health 
protective initiative of Proposition 65 by enacting the California 
Safe Cosmetics Act (CSCA).268  Under the CSCA, California’s 
Department of Public Health runs the California Safe Cosmetics 
Program.269  The Safe Cosmetics Program compiles a list of all 
chemicals known or suspected of causing cancer, birth defects, or 
reproductive harm, and maintains a publicly available database 
containing ingredient information.270 
Central to the CSCA is also the requirement that cosmetics 
manufacturers report to the State Department of Public Health 
any products containing “any ingredient that is a chemical 
identified as causing cancer271 or reproductive toxicity.”272  The 
CSCA specifically requires that ingredients listed as “fragrance,” 
“flavoring,” “other ingredient,” or ingredients otherwise treated as 
a trade secret under federal regulations, must be identified and 
listed.273 
With respect to cosmetics marketed as containing “organic” 
products, regulations under California’s Organic Products Act of 
 
pdf.  The Proposition 65 list now contains approximately 800 substances.  Id. at 
1. 
 268. Amity Hartman, FDA’s Minimal Regulation of Cosmetics and the Daring 
Claims of Cosmetic Companies That Cause Consumers Economic Harm, 36 W. 
ST. U. L. REV. 53, 68-69 (2008); see CAL. HEALTH & SAFETY CODE §§ 111791-
111793.5. 
 269. California Safe Cosmetics Program, CAL. DEP’T OF PUB. HEALTH, 
http://www.cdph.ca.gov/programs/cosmetics/Pages/default.aspx (last visited Feb. 
21, 2014) [hereinafter California Safe Cosmetics Program]. 
 270. California Safe Cosmetics Program, supra note 269. 
 271. The CSCA defines “[c]hemical identified as causing cancer or 
reproductive toxicity” as a substance: (1) “known or reasonably anticipated to be 
a human carcinogen in a National Toxicology Report on carcinogens”; (2) 
evaluated to be a carcinogen by the International Agency for Research on 
Cancer; (3) identified as a known or likely carcinogen by the EPA; or (4) a 
“substance identified as having some or clear evidence of adverse 
developmental, male reproductive, or female reproductive toxicity effects in a 
report by an expert panel of the National Toxicology Program’s Center for the 
Evaluation of Risks to Human Reproduction.”  CAL. HEALTH & SAFETY CODE § 
111791.5(b)(1)-(4). 
 272. Id. § 111792(a); Hartman, supra note 268, at 69.  Manufacturers with less 
than $1 million of cosmetics sales within and outside of California would not be 
subject to the requirement to report the use of materials that cause cancer or 
have reproductive toxicity.  CAL. HEALTH & SAFETY CODE § 111792(d). 
 273. CAL. HEALTH & SAFETY CODE § 111792(a)(1)-(2). 
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2003274 have been promulgated requiring that cosmetic products 
with labels stating “organic” must have “at least 70% organically 
produced ingredients.”275  In contrast, neither federal law nor 
FDA regulations police the meanings of the terms “natural” or 
“organic” with respect to cosmetic products.276 
V.   PROSPECTIVE U.S. REGULATION 
A.  Federal Proposals: Mistakes from the Past 
Current proposals to improve the safety of U.S. cosmetics 
regulation generally do not go far enough to effect changes in the 
overall regulatory paradigm.277  They continue to operate from 
the stance that a chemical or product formulation is safe until 
proven otherwise.278  Several new proposals for federal law in 
recent years have, however, attempted to strengthen U.S. 
cosmetics regulation within the existing toxics regulation 
paradigm.  The Safe Cosmetics and Personal Care Products Act, 
introduced by Congresswoman Jan Schakowsky (D-Ill.) and 
currently in committee, goes furthest, requiring prospective 
safety information, prior to the marketing of a cosmetic 
product.279 
The proposed Enhancement Act, introduced in 2012,280 would 
have amended the FDCA to require the registration of cosmetic 
products and cosmetic manufacturing facilities.281  A facility’s 
registration would have been subject to suspension for violations 
of the FDCA if such violations could have resulted in serious 
adverse health consequences or death to humans or animals.282 
 
 274. See id. §§ 110810-110959. 
 275. Hartman, supra note 268, at 70 (internal quotation marks omitted). 
 276. See id. 
 277. See infra notes 279-364 and accompanying text. 
 278. Id. 
 279. See H.R. 1385, 113th Cong. (2013); infra notes 319-364 and accompanying 
text. 
 280. See H.R. 4262, 112th Cong. (2012).  Rep. Frank Pallone, Jr. (D-N.J.) 
introduced the Enhancement Act, and the bill was referred to the House 
Committee on Energy and Commerce on March 26, 2012.  Id. 
 281. Id. § 2(c). 
 282. Id. 
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 The Enhancement Act boldly called for cosmetic 
manufacturers to establish a file of scientific evidence 
demonstrating a product’s safety before introducing the cosmetic 
product into commerce.283  It defined “safe” as “evidence in the 
file established [pursuant to the Enhancement Act] 
demonstrat[ing] that there is a reasonable certainty that no harm 
will result from the use of the cosmetic product under the 
intended conditions of use for such cosmetic product.”284 
Manufacturers, packers and distributers would have also 
been required to submit to the FDA, within fifteen business days 
of receipt, reports of any serious adverse event which they 
received regarding the use of their cosmetics in the United States, 
and to have maintained records of all information about serious 
adverse effects for a period of six years.285  For this purpose, the 
Enhancement Act defined “serious” as: “(A) resulting in—(i) 
death; (ii) a life-threatening experience; (iii) inpatient 
hospitalization; (iv) a disability, disfigurement, or incapacity; or 
(v) a congenital anomaly or birth defect; or (B) requiring, based on 
reasonable medical judgment, a medical or surgical intervention 
to prevent [any of the previously listed outcomes].”286  Cosmetics 
manufacturers would have needed to make available to the FDA 
all records regarding cosmetic products that are misbranded or 
adulterated under the FDCA.287 
The Enhancement Act also called for the Secretary of Health 
and Human Services, (the Secretary), to promulgate new 
regulations establishing “good manufacturing practices for 
cosmetics,”288 and products not made in accordance with good 
manufacturing practices would have been designated as 
“adulterated” under the FDCA.289  In addition, the bill would 
have allowed manufacturers to voluntarily recall a cosmetic 
product that was likely adulterated where the use of the product 
 
 283. Id. § 3(b). 
 284. Id.  The Enhancement Act would also have required the payment of $500 
by each registering facility for annual registration fees, beginning in 2013.  Id. § 
2(d).  This fees provision was scheduled to sunset, with no fees authorized after 
2017.  Id. 
 285. H.R. 4262 § 4(c), 112th Cong. (2012). 
 286. Id. § 4(c). 
 287. Id. § 5(a). 
 288. Id. § 6(b). 
 289. See id. §§ 2(b), 6(a). 
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would cause serious adverse health consequences or death to 
humans, and it would have allowed the FDA to order a 
mandatory recall if a voluntary recall is not obtained.290 
While a law introduced along the lines of this bill would have 
been an improvement over current law, given the inclusion of 
FDA authority to issue a recall, and the limited requirements 
that manufacturers show product safety before it goes to market, 
the Enhancement Act was lacking in its failure to attack the 
issue of trade secrets and proprietary information in consumer 
cosmetic products.291  Additionally, the efficacy of the somewhat 
ambiguous language requiring “good manufacturing practices” is 
questionable, given the FDA’s history of deferring to industry in 
terms of adopting any new manufacturing rules.292 
The Amendments Act, another federal legislative proposal, 
introduced by Rep. Leonard Lance (R-N.J.) in 2012,293 also 
required the registration of cosmetics manufacturers and of 
cosmetic products.294 
Only manufacturers performing the final steps of the 
manufacturing process would have been required to register, and 
the registration would have consisted of the company’s name, 
 
 290. Id. § 7(b). 
 291. The Enhancement Act is silent on the matter of trade secrets or 
proprietary information.  Furthermore, serious adverse event reports would be 
classified as medical files that are not subject to public disclosure.  H.R. 4262 § 
4(c), 112th Cong. (2012). 
 292. See, e.g., Schaffer, supra note 66, at 200-01.  Schaffer describes the 
history of good manufacturing practices for eye makeup as follows: 
In 1977, FDA announced that it intended to institute Good 
Manufacturing Practices for eye makeup preservatives as a first step 
towards Good Manufacturing Practices for all types of cosmetics.  
Rather than protesting against such imposition of Good 
Manufacturing Practices, the [Cosmetic, Toiletry and Fragrance 
Association] merely filed a petition stating what the industry would 
prefer to see in Good Manufacturing Practices.  FDA then 
incorporated the cosmetics industry’s petition into the Good 
Manufacturing Practice guidelines featured in the FDA 
‘Investigations Operations Manual.’  Since then, FDA has removed 
the guidelines and so ended federal cosmetics Good Manufacturing 
Practices altogether. 
Id. 
 293. See H.R. 4395, 112th Cong. (2012). 
 294. Id. §§ 3-4. 
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address, and other contact information.295  The FDA could have 
thus suspended a manufacturer’s registration for violations of the 
FDCA, where such violation presented a “significant risk of 
serious adverse health consequences or death to humans.”296  The 
bill called for exceptions to product registration, where 
manufacturers had previously filed voluntary cosmetic ingredient 
statements that contained what the FDA has determined to be 
confidential trade secrets.297  This allowance for the continuation 
of the “trade secret formulation” severely weakened the bill. 
As under the Enhancement Act, the Amendments Act would 
have required the filing of unexpected, adverse event reports with 
the FDA within fifteen business days,298 but it did not require the 
filing of a report for an adverse event that was listed on the 
current labeling.299  The Amendments Act also specifically stated 
that adverse effect reports do not “constitute an admission that 
the cosmetic involved, caused or contributed to the adverse 
event.”300  The Amendments Act explicitly stated that, “a 
cosmetic shall be deemed to be safe if it does not present a risk of 
significant illness or injury to humans under the conditions of use 
recommended or suggested in the labeling.”301 
The Amendments Act would also have required the Secretary 
to issue rules establishing good manufacturing processes for 
cosmetic products.302  In contrast to the Enhancement Act, under 
the Amendments Act, cosmetic products made in ways that did 
not follow good manufacturing processes would not have been 
automatically considered to be adulterated. 
 
 295. Id. § 3. 
 296. Id.  Note that, unlike the Enhancement Act, this provision does not 
address health consequences or death to animals.  H.R. 4262 § 2(c), 112th Cong. 
(2012). 
 297. H.R. 4395 § 4, 112th Cong. (2012).  Note that the actual text of the 
Amendments Act regarding these exceptions is inaccurate in its cross-references 
to existing regulations.  It refers to cosmetic ingredient statements filed under 
21 C.F.R. § 710, although such statements are authorized under 21 C.F.R. § 
720.8(b).  Section 710 actually concerns the voluntary registration of cosmetic 
product establishments (manufacturers and packers). 
 298. H.R. 4395 § 5, 112th Cong. (2012). 
 299. See id. 
 300. Id. 
 301. Id. § 12. 
 302. Id. § 6. 
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The Secretary would also have been permitted, or required in 
response to a petition, to establish tolerance levels for 
nonfunctional constituents in cosmetics.303  In this manner, this 
bill introduced the questionable QRA process that governs so 
much of toxics regulation.304  A “nonfunctional constituent” in a 
cosmetic is defined as “any substance that is an ancillary part of 
an ingredient or the manufacturing process, has not been added 
as a separate substance, and serves no cosmetic function in the 
cosmetic.”305  The law would thus have required that the 
tolerance level be set at a level that is “necessary for the 
protection of the public health using generally recognized 
principles of scientific risk assessment,” and required risk 
assessors to consider what is “reasonably achievable through good 
manufacturing practices,” and ensure that such tolerance level is 
consistent with that established by authoritative scientific or 
regulatory organizations.306  As noted elsewhere in this article, 
while signaling recognition of potential risk, this proposed 
reliance upon the highly subjective QRA process with respect to 
cosmetics—many containing EDCs—would be extremely 
problematic.307  This is especially true with the bill’s limitation in 
setting any tolerance to that which is “reasonably achievable,” 
opening the door to a potential weakening of the safety 
standard.308 
Another extremely significant problem with the Amendments 
Act was that findings in a final report by the CIR Expert Panel, 
privately organized and funded by the cosmetics industry,309 
regarding the safety of a cosmetic product would have been 
deemed recommendations to the Secretary, and would have been 
accepted unless the Secretary specifically determined 
otherwise.310  The bill stated that the CIR Expert Panel could 
determine whether a cosmetic ingredient: 
 
 303. Id. § 7. 
 304. See Watnick, supra note 68, at 1316-26. 
 305. H.R. 4395 § 7, 112th Cong. (2012). 
 306. H.R. 4395 § 7, 112th Cong. (2012). 
 307. See supra notes 97-104 and accompanying text. 
 308. Id. 
 309. About the Cosmetic Ingredient Review, COSMETIC INGREDIENT REV., 
http://www.cir-safety.org/ about (last visited Feb. 21, 2014). 
 310. H.R. 4395 § 8, 112th Cong. (2012). 
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(1) is safe for use in cosmetic products without the need for 
specified conditions of use; (2) is safe for use in cosmetic products 
under specified conditions for use; (3) is not safe for use in a 
cosmetic product under any conditions of use; [or] (4) requires 
more information in order to make a determination whether the 
ingredient is safe for use in a cosmetic product under any 
conditions or use. . . .311 
Thus, the Secretary could ban cosmetic ingredients that fall 
under determinations (3) and (4), or (2) if there were 
noncompliance with applicable conditions.  This reliance on an 
industry organization, where the Secretary does not generally 
have the resources to “determine otherwise” also weakened this 
bill considerably.312 
The Amendments Act also permitted—or required, in 
response to a petition—the Secretary to evaluate the safety of any 
ingredient in a cosmetic product, and establish conditions for the 
safe use of such ingredient.313  Again, this presumed that the 
Secretary had the resources and political will to identify and then 
test suspicious ingredients or products—a specious presumption 
at best. 
The proposed Amendments Act would also have authorized 
the creation of a National Cosmetic Regulatory Databank, which 
would have included: cosmetic manufacturing registrations; 
cosmetic ingredient statements; adverse event reports; and other 
information deemed appropriate.314  The Secretary would also 
have been given access to company records to determine whether 
a cosmetic product was adulterated and presented a threat of 
serious adverse health consequences or death to humans.315  This 
access to records was, however, significantly limited by the 
condition that the provision “[did] not extend to cosmetic product 
formulas,” and other potentially proprietary data.316 
Another provision in the Amendments Act would have 
prohibited states or localities from establishing laws regarding 
 
 311. Id. 
 312. See supra notes 37-40, 64-69 and accompanying text. 
 313. H.R. 4395 § 9, 112th Cong. (2012). 
 314. See id. § 10. 
 315. Id. § 11. 
 316. Id. 
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cosmetics that differ from the requirements of the FDCA, or from 
rules promulgated by the Secretary.317  The Amendments Act did 
provide that imported cosmetics would have to have cosmetic 
establishment registration numbers and cosmetic ingredient 
statement numbers—numbers that are now only voluntarily 
provided by importers.318 
B.  The Safe Cosmetics and Personal Care Products       
Act of 2013 
The Safe Cosmetics and Personal Care Products Act of 2013 
(SCA),319 the strongest of the three recent federal proposals, and 
the one that is currently in the House of Representatives that 
would amend the FDCA, was first introduced under a slightly 
different name in the House of Representatives during 2011.320  
The SCA was a revised version of the 2010 Safe Cosmetics Act, 
which did not survive committee.321  The SCA provides for the 
mandatory registration of cosmetic products manufacturers.322  
Registration would include all cosmetic products made, gross 
sales from such products, and the source and name of ingredients 
received from other entities.323  Under the SCA, the Secretary 
would compile a list of all registered establishments and make 
such list available to the public.324  Registered establishments 
would also need to pay an annual registration fee, as set by the 
Secretary, which would vary based on the establishment’s gross 
 
 317. Id. § 14. 
 318. See id. § 15; see Voluntary Cosmetic Registration Program (VCRP), FDA, 
http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/Volu
ntaryCosmeticsRegistrationProgramVCRP/#Registering_establishments (last 
visited Feb. 28, 2014). 
 319. See H.R. 1385, 113th Cong. (2013). 
 320. See Tobias J. Gillett, Note, Lessons from Nutritional Labeling on the 20th 
Anniversary of the NLEA: Applying the History of Food Labeling to the Future of 
Household Chemical Labeling, 37 WASH. U. J.L. & POL’Y 267, 294 (2011). 
 321. Id. at 294 n. 181. 
 322. H.R. 1385 § 612(a).  Microbusinesses, defined as businesses with less 
than $2 million in annual sales receipts for cosmetic products, would be exempt 
from registration under the SCA.  Id. §§ 611(7), 612(a)(1). 
 323. See id. § 612(b). 
 324. Id. § 612(d). 
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receipts or sales, and would only be imposed on companies with 
annual gross receipts or sales in excess of $10 million.325 
The SCA would also change the reporting of cosmetic 
ingredients.  “Ingredient” would be specifically defined to include 
the components of a “fragrance, flavor or preservative,”326 thus 
eliminating the “trade secret” loophole.327  Additionally, the 
ingredient list would be required to incorporate any contaminants 
that are present at more than the lower of: (1) “one part-per-
billion by weight of product formulation;” or (2) “one percent of 
the restriction on the concentration for such contaminant for such 
use, as determined [on the list of restricted ingredients].”328  The 
SCA would also authorize the Secretary to require ingredients to 
be specifically labeled as “nano-scale” if particles are 100 
nanometers or smaller in at least one dimension, or require other 
scale-specific ingredient information if such ingredients pose 
scale-specific hazards.329  Web pages selling cosmetics would 
similarly be required to present complete ingredients lists.330 
The SCA also calls for the Secretary to establish safety 
standards for cosmetics and ingredients that provide a reasonable 
certainty of no harm from exposure and protect consumers “from 
any known or anticipated adverse health effects . . . .”331  
“Reasonable certainty of no harm” is defined as no harm caused 
to members of the general public or any vulnerable population332 
from aggregate exposure, taking into account low-dose exposures, 
additive effects from repeated exposure over time, and cumulative 
exposure from all sources including from cosmetic and 
environmental sources.333  Safety standards would be intended to 
meet either of two tests: (1) likely exposure will not result in 
 
 325. Id. § 612(e). 
 326. Id. § 611(5)(E). 
 327. Id. § 613(f); see supra notes 183-88 and accompanying text. 
 328. H.R. 1385 § 613(c), 113th Cong. (2013). 
 329. Id. § 613(d). 
 330. Id. § 613(e). 
 331. Id. § 614(a)(1). 
 332. “Vulnerable populations” under the SCA would include “pregnant women, 
infants, children, the elderly, and highly exposed populations, including workers 
employed by hair salons, nail salons, beauty salons, spas, other establishments 
that provide cosmetic treatment services for humans, and cosmetic 
manufacturing plants.”  Id. § 611(13). 
 333. Id. § 611(9). 
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“more than a one-in-a-million risk for any adverse health effect in 
any vulnerable population at the lower 95th percentile confidence 
interval;” or (2) exposure will produce no adverse health effects 
with a margin of safety of at least 1000, and considering 
cumulative exposure from all sources.334  The SCA would also 
require the Secretary to establish good manufacturing practices 
for cosmetics manufacturers.335  The inclusion of this one-in-a-
million standard is generally considered to be a negligible risk 
standard.336  Moreover, the addition of the vulnerable population 
as the benchmark, as well as recognition of the potential long-
term effects of consumer cosmetic products, makes the standard 
considerably more health protective than other ostensibly health-
based standards.337 
Manufacturers would thus be required under the SCA to 
provide to the FDA all information regarding safety of their 
cosmetics and ingredients.338  This safety data would include 
information functions and uses, information on physical, 
chemical, and toxicological properties, exposure and rate 
information, and the results of all safety tests.339  The FDA would 
also be required to establish a publicly available database of all 
non-confidential safety information provided.340  The FDA would 
use this information, as well as information from other 
authoritative sources, to evaluate the safety of cosmetics and 
their ingredients, specifically considering the potential harms of 
nanomaterials.341 
The SCA would also establish lists of prohibited, restricted, 
and “safe without limits” ingredients for use in cosmetic products, 
in a manner akin to the EU cosmetics regulations.342  To 
determine the placement of substances on any of the lists, the 
FDA would take into account whether the substance: (1) reacts 
 
 334. H.R. 1385 § 614(a)(2)(A)-(B), 113th Cong. (2013). 
 335. Id. § 614(b)(1). 
 336. Watnick, supra note 97, at 1337. 
 337. Our past failure to consider vulnerable populations such as children and 
pregnant woman has been the author’s long-time criticism of U.S. toxics 
regulatory frameworks.  Watnick, supra note 97, at 1320-24. 
 338. H.R. 1385 § 615(a)(1)(A)-(B), 113th Cong. (2013). 
 339. Id. § 615(a)(2)(A)-(D). 
 340. Id. § 615(b)(1). 
 341. Id. § 615(c)(1)-(2). 
 342. Id. § 616(a)(1)(A)-(B). 
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with other substances; (2) is found in the body; (3) is found in 
drinking water or air; (4) is a “known or suspected neurological or 
immunological toxicant, respiratory asthmagen, carcinogen, 
teratogen, or endocrine disruptor, or [has] other toxicity concerns 
(including reproductive or developmental toxicity)”; or (5) is 
known to persist in the environment or living tissue.343  Under 
the SCA, manufacturers would thus be required to eliminate or 
restrict the use of ingredients on the prohibited or restricted lists 
within one year of listing.344  A further priority assessment list 
would be established for items that cannot be otherwise listed for 
lack of information, and for which a safety determination is a 
priority.345  If, within five years of placement on the priority 
assessment list, there is insufficient information to list the 
substance on the prohibited, restricted, or “safe without limits” 
lists, such ingredient would be prohibited from use in cosmetic 
products.346 
Cosmetic products made of only ingredients in the “safe 
without limits” use or the restricted list—where such use is in 
compliance with the restrictions on the use—would be presumed 
to meet safety standards.347  However, manufacturers might be 
required to establish a product’s safety if it “contains penetration 
enhancers, sensitizers, estrogenic chemicals, or other similar 
ingredients,” or contains ingredients that interact to form 
harmful byproducts.348  This latter requirement seems aimed at 
protecting against interactions in products as seen in the baby 
shampoo news headlines.349 
The FDA would be mandated under the SCA to establish a 
list of: (1) cosmetic ingredients that may contain contaminants; 
(2) ingredient combinations that may create contaminants; (3) 
 
 343. Id. § 616(a)(2)(A)-(E).  The SCA defines “reproductive or developmental 
toxicity” as contributing to “biologically adverse effects on the development of 
humans or animals, including effects on the female or male reproductive system, 
the endocrine system, fertility, pregnancy, pregnancy outcomes, or modifications 
in other functions of the body that are dependent on the integrity of the 
reproductive system as well [as] normal fetal development.  Id. § 611(10). 
 344. H.R. 1385 § 616(b)(4)(A)-(B), 113th Cong. (2013). 
 345. Id. § 616(d)(1)(A)-(B). 
 346. Id. § 616(d)(6)(A). 
 347. Id. § 617(b)(1)(A)-(C). 
 348. Id. § 617(b)(2)(A)-(B). 
 349. See supra notes 3-5 and accompanying text. 
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contaminants that may leech from product packaging; or (4) any 
other cosmetic contaminant.350  The FDA then would establish 
testing procedures for the listed contaminants.351  The FDA 
would be required to respond within six months to reasonable 
petitions to add items to the prohibited, restricted, or priority 
assessment lists, remove items from the “safe without limits” list, 
or add items to the list of contaminants.352  In this way, the FDA 
would, for the first time, have to promptly respond to consumer 
concerns regarding cosmetic formulations. 
Also under the SCA, brand owners would be required to 
report adverse health effects to the FDA.353  Such reports would 
be made accessible to the public, with redactions for personally 
identifiable information.354  Another provision of the SCA 
specifically provides that any non-confidential information 
submitted to the FDA would be made available to the public, 
including: (1) the name, identity, and structure of substances, 
contaminants, or impurities; (2) information regarding “the 
function, exposure, toxicity data, health hazards, and 
environmental hazards for a cosmetic;” (3) the function of 
ingredients in a cosmetic; and (4) cosmetic fragrance, flavor, and 
colorants.355  The concentration of ingredients, however, in a 
finished product would be considered confidential business 
information, and would not be made available to the public.356  
Entities would be permitted to petition for information to remain 
confidential by showing that the release would have a serious 
negative impact on its commercial interests, although the FDA 
could choose to not prevent the disclosure of: (1) the name, 
identity, and structure of an ingredient, contaminant, or 
impurity; or (2) the health and safety data related to the 
ingredient, contaminant, or impurity.357  And finally, any 
cosmetic brand owner, manufacturer, packager, retailer, or 
distributor with reason to believe that a cosmetic is “adulterated 
 
 350. H.R. 1385 § 618(a)(1)-(4), 113th Cong. (2013). 
 351. Id. § 618(c). 
 352. Id. § 621(a)(1)-(4). 
 353. H.R. 1385 § 622(a), 113th Cong. (2013). 
 354. See id. § 622(d)(1)-(2). 
 355. Id. § 623(a)(1)-(4). 
 356. Id. § 623(b). 
 357. Id. § 623(c)(1)-(2). 
53
  
648 PACE ENVIRONMENTAL LAW REVIEW [Vol.  31 
or misbranded in a manner that presents a reasonable 
probability” of causing severe adverse health effects or death 
would have to notify the Secretary.358 
Under the SCA, the FDA would thus have the clear authority 
to issue a voluntary recall and give notice of this recall if it 
believed a cosmetic was adulterated, misbranded, or otherwise in 
violation of the FDCA (as amended).359  And, if this voluntary 
recall were not observed, to order that the product sales cease, 
and to ultimately order a mandatory recall.360 
The SCA would also mandate that the FDA establish 
alternative testing procedures to minimize the testing of 
ingredients and cosmetics on animals.361  Under the SCA, the 
FDA would also conduct annual tests of random cosmetic 
samples, testing for “negative reactions, pathogen hazards, 
contaminants, leaching of packaging additives, mislabeling, or 
other relevant issues of concern . . . .”362 
The SCA would likewise significantly broaden the definitions 
of adulterated and misbranded cosmetics to include cosmetics 
that: (1) do not meet established safety standards; (2) contain 
ingredients on the prohibited list or the restricted list, in excess of 
the limits established by such list; (3) do not properly list or 
package their products; or (4) do not pay fees and report severe 
adverse effects.363  
Overall, the SCA would significantly strengthen U.S. 
cosmetics law by: (1) requiring the registration of cosmetic 
manufacturers; (2) creating a prohibited and “safe without limits” 
list of ingredients; (3) doing away with the trade secret and 
proprietary information loopholes; and (4) requiring 
manufacturers to share safety testing and provide adverse health 
 
 358. Id. § 620(a)(1). 
 359. H.R. 1385 § 620(b), 113th Cong. (2013).  If there was reason to believe 
that a cosmetic might cause serious adverse health effects or death, is 
misbranded, or is manufactured by an unregistered facility, the FDA could issue 
an order stopping distribution of the product or an order to mandatorily recall 
the cosmetic under the SCA.  The FDA might also provide information regarding 
any recall to the general public and to state and local officials.  Id. § 620(c)–(d), 
(f). 
 360. See H.R. 1385 § 620(c), 113th Cong. (2013).   
 361. See id. § 624(a)(1). 
 362. Id. § 625. 
 363. See id. §§ 601, 602. 
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effects information.  Furthermore, the addition of clear FDA 
recall authority under the bill would be a significant and quite 
telling step forward in our effort to regulate U.S. cosmetics to 
protect human health and the environment.  Given the failure of 
earlier versions of this bill to survive committee, the political 
feasibility of such a measure seems questionable absent a 
monumental shift in public awareness and pressure.364 
VI.  CONCLUSION 
Current U.S. cosmetics law and regulations contain 
abundant loopholes and weaknesses, such that they do not 
adequately protect human health.  The current regulatory 
framework does not call for a consideration of the special 
susceptibility of children, pregnant or breastfeeding women, other 
vulnerable populations, the potential for danger from EDCs, or 
the potential for long-term or synergistic harm from synthetic 
chemicals.  It also provides no meaningful recall process for the 
FDA in the cosmetics arena. 
A new regulatory structure should give the FDA recall power, 
and require pre-approval of cosmetic formulations and 
ingredients based on up-to-date safety data before a product goes 
to market, as has been required in other jurisdictions.  If we are 
to become more health protective in our regulation of consumer 
products, the U.S. regulatory paradigm, for cosmetics in 
particular and for all consumer products, must shift to a more 
precautionary approach.  Models for more health protective 
legislation are found in many jurisdictions in the developed 
world, including Europe, Canada, and Japan, and at home, in 
California.  Proposed U.S. legislation to strengthen existing law 
would offer improvements within the existing paradigm, but at 
least two of the most recent federal proposals do not go nearly far 
enough to make human health a priority, and the third proposal, 
the SCA, has not been politically feasible when introduced in 
varying forms in prior Congressional sessions.  Consumer 
awareness and resulting public pressure would go a long way 
 
 364. See supra notes 5, 159 and accompanying text (noting that planned and 
existing corporate changes by Johnson & Johnson and by Walmart were largely 
attributed to public pressure). 
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toward strengthening U.S. cosmetic products regulation to make 
it more health protective. 
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